

BACE455, AN ALTERNATIVE SPLICE VARIANT OF THE HUMAN BETA-SECRETASE

FIELD OF THE INVENTION

5

The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for the screening of therapeutically active drugs. The present invention relates to catalytically active beta-secretase (Memapsin2, BACE) variants, and nucleic acids encoding them. The invention is useful in the identification of agents that inhibit the activity of a particular BACE isoform and thus agents and therapies affecting the genesis, development or progression of neuropathological conditions, including Alzheimer's disease and dementia.

15

BACKGROUND OF THE INVENTION

The importance of alternative RNA splicing in the generation of genetic diversity is now widely recognized as one of the most important ways (along with the use of alternative promoters and alternative polyadenylation) for a single gene to encode more than one mRNA transcript. The pre-mRNA or mRNA isoforms that result from alternative splicing may differ in stability, translatability, or protein sequence encoded, each of which may alter the function of the encoded protein.

This can be best exemplified in the field of apoptosis (Jiang and Wu, Proc. Soc. Exp. Biol. Med. 220: 64-72 (1999)). Alterations in alternative splicing, in particular mutations of the canonical sequences at the intron/exon border, may cause abnormal splicing patterns that affect gene expression and cause disease. Cooper et al. (1998) recently showed that at least 10 % of human inherited diseases involve mutations that create an RNA splicing defect; see e.g., Cooper et al., Nucleic Acids Res. 26: 285-287(1998).

Sporadic mutations in the consensus splicing signals are observed in a wide-range of pathologies such as cancers, neurodegenerative disorders, inflammation/asthma and other metabolic diseases. The RNA splicing defects can include exon skipping, intron retention and new splicing events due to the use of cryptic splicing sites or the creation of new splicing consensus sequences (Lopez, Annu. Rev. Genet. 32: 279-305 (1998)). Alterations in activity, levels, or amino acid sequence of cellular splicing factors may affect the efficiency of

35

splicing or the regulation of alternative splicing. For example, the presence of a single nucleotide in the nucleotide sequence of the Survival Motor Neuron gene regulates the splicing of this gene, and is responsible for spinal muscular atrophy (Lorson et al. Proc. Natl. Acad. Sci. USA, 96: 6307-6311 (1999)). In human brains taken from patients with sporadic
5 Alzheimer's disease, splicing events including a) alterations in the amino acid sequence of the protein presenilin-1 (PS1), caused by a deletion of exon 9 of the ps1 gene, b) deletion of exon 5 of the gene encoding presenilin 2 (the ps2 gene), and c) (in cases of sporadic frontotemporal dementia) aberrant splicing of exon 5 of the ps2 gene have been be implicated in the neuropathology (Isoe-Wada. et al. Eur J Neurol, 6, 163-167 (1999); Sato et
10 al. J. Biol. Chem. 276: 2108-2114 (1991)).

Alzheimer's disease (AD) is a devastating degenerative disorder of the brain with important formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss (Hardy et al. Nat. Neurosci 1:355-358 (1998); Selkoe, D.J. In: Alzheimer disease, Ed 2
15 (Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S., eds), pp 293-310. Philadelphia: Lippincott Williams and Wilkins. (1999)). The most affected regions are cortex, hippocampus, subiculum, hippocampal gyrus, and amygdala. Patients suffering from AD have increased problems with memory loss, intellectual functions and skills, personality changes and schizophrenia. AD is the leading cause of dementia in elderly persons and there
20 is no effective palliative or preventive treatment for the neurodegeneration.

Several genetic and epigenetic factors have been suggested as mechanisms contributing to AD; these include genetic predisposition, infectious agents, toxins, metals, head trauma and vascular dementia. Globally, it is the dysregulation of intracellular pathways
25 responsible for amyloid precursor protein (APP) proteolytic processing that results in enhanced formation of a peptide termed A-Beta (A- β) 1-42 -- a form of the A- β peptide which is particularly amyloidogenic, which now appears to be central to the pathophysiology of AD (Selkoe, Neuron 32: 177-180 (2001)).

30 The A- β peptide is also the primary protein constituent in cerebrovascular amyloid deposits. Amyloid is a filamentous material that is arranged in beta-pleated sheets. The A- β peptide is a hydrophobic peptide comprising up to 43 amino acids. A- β peptide has been shown to be toxic to neurons in a number of ways, including by the induction of reactive oxygen species (ROS), induction of altered gene transcription, causing increased
35 susceptibility to excitotoxicity, and other processes commonly associated with neurodegenerative conditions ((Ramsden et al., J. Neurochem. 79: 699-712 (2001); Shukla et al., J. Cell. Path. 5: 241-249 (2002); Green and Peers, Neurochem. 77: 953-956 (2001);

Kowall et al., *Neurobiol. Aging* 13: 537–542 (1992); MacManus et al., *J. Biol. Chem.* 275: 4713–4718 (2000)). Mutations in APP, Presenilin 1 and 2 (PS1 and PS2, respectively) greatly alter APP processing, resulting in enhanced A- β 1-42 formation. Amyloid plaques are also detected in aged patients with Down's Syndrome who survive up to the age of 30. The observed up-regulation of APP expression in Down's Syndrome is probably a cause of the development of AD in Down's patients (Rumble et al., *N. Engl. J. Med.* 320:1446-52 (1989); Mann, *Neurobiol. Aging* 10: 397-399 (1989)). Amyloid plaques are also present in the normal aging brain, although at a lower number (Vickers et al., *Exp. Neurol.* 141:1-11 (1996)).

The different forms of human APP presently known range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. A number of APP cDNA's have been identified, including the three most abundant forms, APP695 described by Kang et al. (1987) *Nature* 325: 733-736 which is designated as the "normal" APP; the 751 amino acid polypeptide (APP751) described by Tanzi et al. (1988) *Nature* 331: 528-530; and the 770 amino acid polypeptide (APP770) described by Kitaguchi et. al. (1988) *Nature* 331: 530-532. These forms arise from a single precursor RNA by alternative splicing. The A- β peptide, which is common to each of the three splice variants of APP, is derived from a region of APP adjacent to and containing a portion of the transmembrane domain.

Three different proteases process APP *in vivo* (Vassar and Citron, *Neuron* 27: 419–422 (2000)). Alpha-secretase cleaves APP 12 amino acid residues from the luminal surface of the plasma membrane; it is not involved in A- β production. The first step of A β generation is performed by cleavage of APP by β -secretase (BACE), a type I membrane-bound aspartyl protease. BACE cleavage generates a 100-kDa soluble form (sAPP) of the ectodomain – the portion of APP that projects from the cell surface - and a 12-kDa membrane-associated intermediate peptide of 99 amino acids (termed C99) containing the N-terminus of the A β peptide (Vassar et al., *Science* 286(5440):735-41(1999). The C99 peptide is then processed by the protease gamma-secretase to yield various A β peptides differing in size or terminal modification (40-42 and 43 amino acid residues being the most frequent peptides found *in vivo*) (for review, see Selkoe et al., *Nature* 399(6738 Suppl):A23-31 (1999); Tekirian, *J. Alzheimers. Dis.* 3(2):241-248. (2001)). The APP sequence near the β -secretase cleavage site is:

EVKM*DAE.

These residues are labeled P4-P3-P2-P1*P1'-P2'-P3' in standard protease nomenclature with the cleavage site between P1 and P1' marked by *. Mutations in this region, such as the KM to NL mutation (the so-called Swedish mutation), can transform APP into a more preferred substrate for BACE. Hence, amino acid sequence changes in APP that result in increased APP cleavage by BACE increase the likelihood of the development of Alzheimer's (Citron et al., Nature 360(6405): 672-674 (1992)). Experimental evidence suggests that APP processing is sequential and that cleavage of APP by beta-secretase is a prerequisite for gamma-secretase-mediated APP processing. Cleavage within the transmembrane region of APP by gamma-secretase results in the 40/42- residue A β peptide, whose elevated production and accumulation in the brain are the central events in the pathogenesis of Alzheimer's disease (Selkoe, Nature 399:23-31 (1999)). In addition, it is now clear that BACE can again cut A β peptide 40-42 after gamma-secretase to generate a neurotoxic A β 34 peptide, at the expense of Abeta40-42 (Fluhrer et al., J. Biol. Chem. 278(8): 5531-5538 (2003)).

Many of the existing therapeutic strategies for AD have focused on gamma-secretase inhibition. However, it now appears that such strategies may not be sufficient, or even sound, to treat or prevent AD. For example, it is now clear that the C99 peptide itself, which requires BACE and not gamma-secretase cleavage for generation, includes the entire A β peptide, and is neurotoxic when evaluated in cultured cells, also accumulates in the AD brain (Tekirian, J. Alzheimers. Dis. 3(2):241-248. (2001)). Furthermore, gamma-secretase inhibitors have been shown to seriously affect the immune system and result in the accumulation of C terminal APP fragments, which are themselves toxic. In addition, gamma-secretase inhibition may alter the processing of various vital proteins (Doerfler, et al., Proc. Natl. Acad. Sci. U S A 98 :9312-9317 (2001), Ni et al., Science 294: 2179-2181 (2001), Marambaud, et al., EMBO J 21: 1948-1956 (2002), Kim, et al., J. Biol. Chem. 277: 499976-499981 (2002)). While a lack of BACE activity is not inevitably fatal *in utero*, a double-genetic knock-out of the presenilin 1 and 2 genes did prove to be so (Herreman, et al. Proc. Natl. Acad. Sci. USA 96: 11872-11877 (1999)). This toxicity is primarily a result of inhibition of Notch signaling pathway, which is involved in cell-to-cell signaling. Indeed, the Notch receptor and its cognate ligands Jagged and Delta are known substrates of presenilins (De Strooper, et al. Nature 398: 518-522 (1999)) and because the cleavage of Notch and its ligands leads to the release of proteolytic fragments active in cell signaling (LaVoie and Selkoe, J. Biol. Chem. 278(36): 34427-34437 (2003)).

In contrast, the *in-vivo* processing of the β -secretase site of the APP peptide is thought to be the rate-limiting step in A β peptide production (Sinha, S. & Lieberburg, Proc

Natl Acad Sci U S A. 96(20):11049-53 (1999); Vassar, Adv. Drug Deliv. Rev. 54(12):1589-1602 (2002)). BACE does not appear to participate in the generation of other physiologically important proteins (Cai et al., Nat. Neurosci 4: 233-234 (2001); Luo et al., Nat. Neurosci 4: 231-232 (2001)). Therefore, BACE appears as the strongest therapeutic target for decreasing or inhibiting A β generation.

BACE is synthesized as an inactive pro-enzyme. During maturation in the secretory pathway, BACE undergoes glycosylation at 3 of 4 N-linked sites and is separated from its propeptide domain by a member of the proprotein convertase family of proteases. In addition, BACE also undergoes palmitoylation at cysteine residues within its cytoplasmic domain and is phosphorylated at its C terminus. After core glycosylation in the endoplasmic reticulum (ER), BACE is rapidly and efficiently transported to the Golgi apparatus before targeting to the endosomal system (Fluhrer, R. et al.; J Biol Chem. 278(8):5531-5538 (2003)).

To date, three isoforms of BACE have been isolated: BACE476, BACE457 and BACE432. All of these isoforms are in-frame deletions generated by the alternative usage of the exon3 region of the gene, and all of them exhibit much less APP processing activity, if any at all, than BACE501 (Bodendorf, et al., J. Biol. Chem. 276(15):12019-12023 (2001), Zohar et al., Brain Res. Mol. Brain Res. 115(1):63-68 (2003), Tanahashi and Tabira, Neurosci. Lett. 307(1):9-12 (2001)).

SUMMARY OF THE INVENTION

The present invention is drawn to compositions and methods related to the identification of a new isoform of human beta-secretase (BACE), which is selectively expressed by brain tissue from patients suffering from a neuropathological condition (e.g., the human AD brain), which is catalytically active and which is pharmacologically different from the existing other active native BACE isoform BACE501. This new neuropathological-specific isoform of BACE, termed BACE455, has been discovered to result from the deletion of exon 4 and the development of a novel nucleotide and corresponding amino acid sequence present in the junction of exon3 and exon5.

Based on the published crystal structure of native BACE, it is anticipated that the novel isoform BACE455 of the present invention has a similar 3D structure to BACE, with the two aspartate residues within the active site of the protease still facing each other. However, the active site of BACE455 is more open and accessible and is therefore likely to produce

significantly increased levels of A β peptide as compared to the native BACE molecule. In addition, BACE455 lacks an endoproteolytic site that is responsible for BACE inactivation and thus activity regulation in the native molecule. Therefore, compared to BACE and other known BACE isoforms, BACE455 lacks posttranslational regulation, has an altered 3-D structure, and is likely to produce increased levels of pathological A β peptide. BACE455 is significantly different from BACE501 in terms of inhibitory profile. This is shown using a well described inhibitor. Thus, the deletion of exon4 in BACE455 generates a significant pharmacological difference when compared to other known active BACE isoforms.

It is postulated that the observed functional and pharmacological properties of this isoform which distinguish it from native BACE may contribute to and selectively drive pathological conditions in mammals, particularly in human subjects.

Isolated BACE455, as well as distinctive fragments thereof, and corresponding nucleic acids can be used for the diagnosis of neuropathological conditions which are associated with BACE455 and for the screening of drugs, especially inhibitors of BACE455, which are therapeutically active in the treatment of neurological disorders, particularly neuropathological conditions including neurodegenerative disorders and dementia, more preferably disorders now known to be related to A β formation or accumulation such as Alzheimer's disease and related disorders.

In another embodiment of the invention are provided methods for the treatment of neuropathological conditions comprising the administration to affected tissue of an inhibitor of BACE455 transcription, translation, or activity.

By a "neuropathological condition" is meant one or more conditions including, but not limited to, Motor Neuron Disease (ALS), Down's syndrome, Parkinsonian Syndromes, multiple sclerosis, diffuse cerebral cortical atrophy, Lewy-body dementia, Pick disease, mesolimbocortical dementia, thalamic degeneration, bulbar palsy, Huntington chorea, cortical-striatal-spinal degeneration, cortical-basal ganglionic degeneration, cerebocerebellar degeneration, familial dementia with spastic paraparesis, polyglucosan body disease, Shy-Drager syndrome, olivopontocerebellar atrophy, progressive supranuclear palsy, dystonia musculorum deformans, Hallervorden-Spatz disease, Meige syndrome, familial tremors, Gilles de la Tourette syndrome, acanthocytic chorea, Friedreich ataxia, Holmes familial cortical cerebellar atrophy, AIDS related dementia, Gerstmann-Straussler-Scheinker disease, progressive spinal muscular atrophy, progressive bulbar palsy, maculopathies and retinal degeneration, such as Non-Exudative Age Related Macular Degeneration (ARMD),

Exudative Age Related Macular Degeneration, primary lateral sclerosis, hereditary muscular atrophy, spastic paraplegia, peroneal muscular atrophy, hypertrophic interstitial polyneuropathy, hereditary ataxia polyneuritic form, optic neuropathy, diabetic retinopathy, Alzheimer's disease and ophthalmoplegia. Examples of ocular conditions

5 include, but are not limited to, glaucoma, including open angle glaucoma, ocular hypertension, maculopathies and retinal degeneration, such as Non-Exudative Age Related Macular Degeneration (ARMD), Exudative Age Related Macular Degeneration (ARMD), Choroidal Neovascularization, Diabetic Retinopathy, Central Serous Chorioretinopathy, Cystoid Macular Edema, Diabetic Macular Edema, Myopic Retinal Degeneration;

10 inflammatory diseases, such as Acute Multifocal Placoid Pigment Epitheliopathy, Behcet's Disease, Birdshot Retinochoroidopathy, Infectious (Syphilis, Lyme, Tuberculosis, Toxoplasmosis), Intermediate Uveitis (Pars Planitis), Multifocal Choroiditis, Multiple Evanescent White Dot Syndrome (MEWDS), Ocular Sarcoidosis, Posterior Scleritis, Serpiginous Choroiditis, Subretinal Fibrosis and Uveitis Syndrome, Vogt-Koyanagi-Harada

15 Syndrome, Punctate Inner Choroidopathy, Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Acute Retinal Pigment Epitheliitis, Acute Macular Neuroretinopathy; vascular and exudative diseases, such as Diabetic retinopathy, Central Retinal Arterial Occlusive Disease, Central Retinal Vein Occlusion, Disseminated Intravascular Coagulopathy, Branch Retinal Vein Occlusion, Hypertensive Fundus Changes, Ocular

20 Ischemic Syndrome, Retinal Arterial Microaneurysms, Coat's Disease, Parafoveal Telangiectasis, Hemi-Retinal Vein Occlusion, Papillophlebitis, Central Retinal Artery Occlusion, Branch Retinal Artery Occlusion, Carotid Artery Disease (CAD), Frosted Branch Angiitis, Sick Cell Retinopathy and other Hemoglobinopathies, Angioid Streaks, Familial Exudative Vitreoretinopathy; Eales Disease; traumatic, surgical and environmental disorders,

25 such as Sympathetic Ophthalmia, Uveitic Retinal Disease, Retinal Detachment, Trauma, Retinal Laser, Photodynamic therapy, Photocoagulation, Hypoperfusion During Surgery, Radiation Retinopathy, Bone Marrow Transplant Retinopathy; proliferative disorders, such as Proliferative Vitreal Retinopathy and Epiretinal Membranes; infectious disorders, such as Ocular Histoplasmosis, Ocular Toxocariasis, Presumed Ocular Histoplasmosis Syndrome

30 (POHS), Endophthalmitis, Toxoplasmosis, Retinal Diseases Associated with HIV Infection, Choroidal Disease Associated with HIV Infection, Uveitic Disease Associated with HIV Infection, Viral Retinitis, Acute Retinal Necrosis, Progressive Outer Retinal Necrosis, Fungal Retinal Diseases, Ocular Syphilis, Ocular Tuberculosis, Diffuse Unilateral Subacute Neuroretinitis, Myiasis; genetic disorders, such as Retinitis Pigmentosa, Systemic Disorders

35 with Associated Retinal Dystrophies, Congenital Stationary Night Blindness, Cone Dystrophies, Stargardt's Disease And Fundus Flavimaculatus, Best's Disease, Pattern Dystrophy of the Retinal Pigmented Epithelium, X-Linked Retinoschisis, Sorsby's Fundus

Dystrophy, Benign Concentric Maculopathy, Bietti's Crystalline Dystrophy, pseudoxanthoma elasticum; retinal injuries, such as Macular Hole, Giant Retinal Tear; retinal tumors, such as Retinal Disease Associated With Tumors, Congenital Hypertrophy Of The RPE, Posterior Uveal Melanoma, Choroidal Hemangioma, Choroidal Osteoma, Choroidal
5 Metastasis, Combined Hamartoma of the Retina and Retinal Pigmented Epithelium, Retinoblastoma, Vasoproliferative Tumors of the Ocular Fundus, Retinal Astrocytoma, and Intraocular Lymphoid Tumors.

By "isolated" is meant a molecule existing in an environment other than that normally
10 present in nature without human intervention. Thus, for example, "isolated BACE455" includes naturally-produced BACE455 contained in a cell lysate, purified or partially purified BACE455, recombinant BACE455, as well as BACE455 existing within a heterologous host cell or culture, such as tissue culture cell from any organism (including, without limitation, human, rat, monkey or other mammalian cells, bacterial or fungal cells, or
15 insect cells).

In one embodiment of this invention, methods are described which involve the selective inhibition of BACE455 protein activity. Such methods can be used therapeutically to inhibit the progression of neuropathological conditions such as, without limitation,
20 Alzheimer's disease, other dementia, glaucoma, Parkinson's disease, ALS, and the effects of stroke.

In another embodiment, this invention is drawn to the use of BACE455 mRNA encoding BACE455 or a distinctive fragment thereof, BACE455 protein, or any distinctive
25 fragment of the BACE455 protein, to screen for molecules that inhibit the production of A β peptide.

Preferably a fragment of a protein or polypeptide in accordance with the present invention comprises at least 10 amino acids comprising a contiguous amino acid sequence,
30 more preferably at least 9 amino acids comprising a contiguous amino acid sequence, even more preferably at least 8 amino acids comprising a contiguous amino acid sequence, even more preferably at least 7 amino acids comprising a contiguous amino acid sequence, even more preferably at least 6 amino acids comprising a contiguous amino acid sequence, even more preferably at least 5 amino acids comprising a contiguous amino acid sequence.

35

Preferably a fragment of a nucleic acid or polynucleotide in accordance with the present invention comprises at least 30 nucleotides comprising a contiguous nucleotide

sequence, more preferably at least 27 nucleotides comprising a contiguous nucleotide sequence, even more preferably at least 24 nucleotides comprising a contiguous nucleotide sequence, even more preferably at least 21 nucleotides comprising a contiguous nucleotide sequence, even more preferably at least 18 nucleotides comprising a contiguous nucleotide sequence, even more preferably at least 15 nucleotides comprising a contiguous nucleotide sequence.

By "distinctive" when used to describe a nucleic acid encoding the BACE455 protein or a fragment thereof, is meant that the nucleotide sequence of such nucleic acid comprises at least one codon derived from exon 3 immediately proximal to at least one codon derived from exon 5 of the BACE 455 DNA sequence, encodes a protein or fragment thereof that has the same amino acid sequence encoded by such a nucleic acid or fragment, or is exactly complementary to such nucleotide sequence. In a particular embodiment, a distinctive nucleic acid comprises a nucleotide sequence comprising at least 5 contiguous nucleotides present in the junction of exon3 and exon5 of BACE455.

By "distinctive" when used to describe the BACE455 protein or a fragment thereof, is meant a peptide, polypeptide or protein comprising an amino acid sequence encoded by a distinctive nucleic acid encoding the BACE455 protein or a fragment thereof.

The BACE455 protein, distinctive fragments thereof and nucleic acids encoding these molecules can be used by those skilled in the art to design new BACE455 inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology. Such inhibitors are both useful in the diagnosis and treatment and/or prevention of Alzheimer's disease and other neuropathological conditions. Methods for making BACE455 inhibitors may make use of techniques well known in the art, such as, without limitation, combinatorial and other chemical libraries, use of the isolated BACE455 protein or a distinctive fragment thereof in high throughput screening of chemical libraries, rational drug design using medicinal chemistry techniques based on structure-activity relationships, and the like. Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include, for example, 96- and, and 384-well microtiter plates (see Bennett, et al., J. Mol. Recognition, 8:52-58 (1995); and Johanson, et al., J. Biol. Chem., 270(16): 9459-9471 (1995)). Exemplary methods that can be used for making BACE inhibitors have been disclosed in WO 9967221, WO 9967220, WO 9967219, WO 9966934, WO 9932453, WO 9838177, WO 9828268, WO 9822494, WO 9822493, WO 9822441, WO 9822433, and WO 9822430. Methods for making combinatorial libraries of compounds are

disclosed in references such as Turner et al., Biochemistry 40: 10001-10006 (2001) or Grüninger-Leicht et al., J. Biol. Chem. 277: 4687-4693 (2002).

5 BACE455 inhibitors may be chosen from small molecule inhibitors, peptides, antisense oligonucleotides, iRNA, and blocking antibodies. Thus, inhibition of BACE455 includes the use of agents which inhibit BACE455 transcription, splicing, translation, and/or activity *in vivo*.

10 The present invention is preferably, though not exclusively, drawn to BACE455 inhibitors that alternatively exhibit 2-fold, or 5-fold, or 10-fold, or 30-fold, or 100-fold, or 1000 fold, or >1000 fold selectivity in the inhibition of BACE455 as compared to the other known BACE isoforms. Such inhibitors have an improved utility, compared to compounds that lack such selectivity, or which preferably inhibit native BACE rather than BACE455. Selective BACE455 inhibitors having a 2-fold, 5-fold, 10-fold or greater selectivity at
15 inhibiting BACE455 have a number of benefits including greater efficacy at inhibiting pathological disease progression, decreased side effects due to less inhibition of non-pathological A β production, and improved safety due to the increased selectivity of such compounds.

20 The BACE455 protein, nucleic acid, distinctive fragments of these molecules, and BACE455 inhibitors can be used for the purpose of diagnosis of neuropathological conditions. Compounds specifically binding to BACE455 polypeptide or nucleic acid, or to a distinctive fragment thereof, can help identify individuals prone to develop AD. Additionally, BACE455 inhibitors can be used with therapeutic effect for treatment and/or
25 prevention of Alzheimer's disease and conditions associated with elevated levels of A β 40 or 42 peptide, and the accumulation of the peptide in amyloid plaques, as well as other neuropathological conditions.

30 In another aspect of this invention, the novel deletion of exon 4 and the novel junction of exons 3 and 5 may be used to diagnose and/or assess the actual or potential development of a neuropathological condition. For example, through the development of in vitro nucleic acid- and/or antibody-based assays, including quantitative assays, of human tissue or fluids, one can determine whether the patient suffers from, or is inclined to suffer from, neuropathological conditions that involve the production and expression of BACE455. Such
35 assay methods may involve, without limitation, nucleic acid detection by, for example, Northern Blot, oligonucleotide-based junction array; nucleic acid amplification methods such as RT-PCR, quantitative PCR and ligation-PCR and other methods. These methods may

include the use of an oligonucleotide probe capable of selectively or specifically detecting the region of the analyte comprising the new splice junction. BACE455 may also be directly detected using specific ligands thereof, for example, an antibody specifically recognizing the region of BACE455 comprising the new splice junction, as one example, the region
5 comprising amino acid residues 190 to 235 of the BACE455 protein.

In yet another embodiment, the present invention includes bacterial, insect and mammalian cells or cell lines and transgenic non-human animals that specifically express the BACE455 isoform or a distinctive fragment thereof, in preference to the native BACE501 or
10 other isoforms. Preferred host cells are mammalian cells. Non limiting examples of suitable mammalian cells include the NIH3T3 line of mouse embryo cultures (Jainchill et al. J. Virol. 4: 549-553 (1969)), Chinese hamster ovary cells (CHO), human embryonic kidney cell line 293 or neuroblastoma cell line SH-SY5Y cell line (Biedler et al. Cancer Res. 38: 3751-3757 (1978)). For example, cell lines specifically expressing the BACE455 isoform can be
15 obtained by (a) transfecting a BACE455 expression vector, such as, for example, a pCDNA3 vector with BACE455 full length cDNA cloned into the expression cassette, into the cell type of interest and (b) selecting transfected cells using antibiotics or selection agents corresponding to the resistance gene encoded by the expression vector. Methods for the generation of clonal cell lines composed by stable transformant are disclosed, for example, in
20 Wigler et al. (Cell 11: 223-232 (1977)); Kriegler (Gene Transfer and Expression. Stockton Press, New York, New York (1990)) or Gramer & Gooch (Biotechnol. Prog. 9(4):366-73 (1993)). Alternatively, transfected cells can be used in transient transfection assays to monitor BACE455 activity without further selection. Transgenic animals may be obtained, as known in the art, by recombination techniques using methods well known in the art of
25 molecular biology which are described in such reference as Sambrook et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor N.Y. (1988)) and Ausubel (Current Protocols in Molecular Biology (1989)).

Such cell lines represent an original screening tool for compounds preventing A β processing, and non-human transgenic animals would be useful for studying the development
30 of A β -dependent dementia and for identifying compounds that inhibit A β dependent disease progression *in vivo*.

BRIEF DESCRIPTION OF THE DRAWINGS

35 **Figure 1** : Nucleic (A, SEQ ID NO: 1) and amino acid (B, SEQ ID NO: 2) sequence of BACE455 and alignment of amino acid sequence with BACE501.

Figure 2 : BACE455 (A, C) and BACE501 (B, D) immunolocalization on NIH 3T3 cells transfected with a construct expressing BACE455 or BACE501. A, B: Intracellular staining of BACE isoforms on Triton X100- permeabilized cells using polyclonal anti-hBACE (481-501) (C-ter intracellular epitope). C,D: Extracellular staining of BACE isoforms on non-permeabilized cells using polyclonal anti-hBACE (46-65) (N-ter extracellular epitope). Photomicrograph showing that BACE455 presents similar intracellular localization than BACE501, is efficiently exported to the cellular membrane where it displays comparable extracellular membranous immunoreactivity to BACE501.

Figure 3: BACE455 and BACE501 display different inhibitory profile using the commercially available BACE inhibitor III in the fluorogenic assay. Shown results are percentage of activity +-SEM in 3 independent experiments.

Figure 4: Effects of BACE455 on the production of C99 fragment from endogenously expressed APP isoforms in SH-SY5Y cells transfected with the empty vector (Mock, M) or with a construct expressing BACE455 (B). MW: molecular weight

Figure 5: C99 peptide generation from endogenously expressed APP isoforms in SH-SY5Y cells transfected with a construct expressing BACE455 is inhibited by Brefeldin A (BFA) and Gleevec.

DETAILED DESCRIPTION OF THE INVENTION

In a first embodiment, the present invention is drawn to a polypeptide comprising all or a distinctive fragment of the BACE455 polypeptide. The BACE455 amino acid sequence is depicted in Figure 1. The term "BACE 455" or "BACE455 polypeptide" means any BACE polypeptide (preferably of human origin), that comprises a deletion of all or part of exon 4 of the gene encoding the wild-type BACE peptide.

Preferred examples of distinctive fragments of the BACE455 polypeptide are those comprising the amino acid sequence IARIIG (SEQ ID NO: 3). Further examples of such fragments are polypeptides comprising the amino acid sequence EIARIIG (SEQ ID NO: 4), typically a sequence selected from EIARIIGG (SEQ ID NO: 5), AEIARIIG (SEQ ID NO: 6), AEIARIIGG (SEQ ID NO: 7), AEIARIIGGI (SEQ ID NO: 8), YAEIARIIG (SEQ ID NO: 9), YAEIARIIGG (SEQ ID NO: 10) and YAEIARIIGGI (SEQ ID NO: 11). Most preferred fragments are at least 6, 7, 8, 9 or 10 amino acids long.

A polypeptide of the present invention comprising a distinctive BACE455 polypeptide fragment may comprise the entire amino acid sequence of BACE455 or a variant thereof. The term "variant" in this context designates any polypeptide comprising a distinctive fragment of the BACE455 polypeptide and further comprising a modified amino acid sequence as compared to the sequence depicted in Figure 1 as a result of one or several amino acid mutation(s), substitution(s) and/or insertion(s). Typically, such BACE455 variants lack all of exon 4. Preferred variants are naturally-occurring variants, i.e., BACE polypeptides resulting from polymorphism, splicing, etc., which lack exon 4. Most preferred polypeptides of this invention are of human origin and/or retain one property of BACE455 of Figure 1, in particular at least one BACE455-selective immunological property and/or a beta-secretase activity.

Such polypeptides may optionally comprise additional residues or functions, such as, without limitation, additional amino acid residues, chemical or biological groups, including labels, tags, stabilizer, targeting moieties, purification tags, secretory peptides, functionalizing reactive groups, etc. Such additional residues or functions may be chemically derivatized, added as an amino acid sequence region of a fusion protein, complexed with or otherwise either covalently or non-covalently attached. They may also contain natural or non-natural amino acids. The polypeptide may be in soluble form, or attached (or complexed with or embedded in) to a support, such as a matrix, a column, a bead, a membrane, a cell, a lipid or liposome, etc.

Certain polypeptides of the present invention may be used as such to cause production of A β peptide in vitro or in vivo. They may also be used to design specific reagents such as peptides, antibodies (and derivatives thereof), antagonists, agonists, etc. that specifically detect, bind or affect expression or activity of a BACE455 polypeptide as defined above. The polypeptides may also be used as immunogens in vaccine compositions or to produce or detect or dose specific antibodies.

In yet another embodiment, the present invention comprises a polynucleotide comprising a nucleotide sequence encoding a BACE455 polypeptide as defined above, including a distinctive fragment thereof. The polynucleotide preferably encodes a polypeptide that comprises a fragment of mammalian memapsin 2 (BACE) protein, wherein said polypeptide lacks all of exon4 (encoded by amino acids 190 to 235 of full-length BACE protein). A typical example of such a polypeptide comprises all or a distinctive fragment of the nucleotide sequence set forth in Figure 1 (SEQ ID NO: 2).

A particular embodiment of this invention also includes any polynucleotide comprising a nucleotide sequence that selectively hybridizes to a distinctive fragment of BACE 455 RNA (or its exact complement) under stringent conditions. More preferably, such selectively hybridizing polynucleotide encodes a polypeptide having beta-secretase activity.

5 By stringent conditions is intended, for example, incubations of hybridization filters at about 42° C for about 2.5 hours in 2 X SSC/0.1%SDS, followed by washing of the filters four times of 15 minutes in 1 X SSC/0.1% SDS at 65° C. Protocols used are described in such reference as Sambrook et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor N.Y. (1988)) and Ausubel (Current Protocols in Molecular

10 Biology (1989)).

In a particularly preferred embodiment, the encoded BACE polypeptide comprises a distinctive fragment of a human BACE protein.

15 The nucleic acids, oligonucleotides and polynucleotides of the present invention may be DNA or RNA, such as genomic DNA, complementary DNA, synthetic DNA, mRNA, or analogs of these containing, for example, modified nucleotides such as 3'alkoxyribonucleotides, methylphosphanates, and the like, and peptide nucleic acids (PNAs), etc. The polynucleotide may be produced according to techniques well-known per

20 se in the art, such as by chemical synthetic methods, in vitro transcription, or through recombinant DNA methodologies, using sequence information contained in the present application. In particular, the polynucleotide may be produced by chemical oligonucleotide synthesis, library screening, amplification, ligation, recombinant techniques, and combination(s) thereof.

25

A specific embodiment of this invention resides in a polynucleotide encoding a polypeptide comprising a distinctive fragment of BACE having the amino acid sequence set forth as SEQ ID NO 2.

30 Polynucleotides of this invention may comprise additional nucleotide sequences, such as regulatory regions, i.e., promoters, enhancers, silencers, terminators, and the like that can be used to cause or regulate expression of a BACE455 polypeptide.

Polynucleotides of this invention may be used to produce a recombinant polypeptide

35 of this invention. They may also be used to design specific reagents such as primers, probes or antisense molecules (including antisense RNA, iRNA, aptamers, ribozymes, etc.), that specifically detect, bind or affect expression of a polynucleotide encoding a BACE455

polypeptide as defined above. They may also be used as therapeutic molecules (e.g., as part of an engineered virus, such as, without limitation, an engineered adenovirus or adeno-associated virus vector in gene therapy programs) or to generate recombinant cells or genetically modified non-human animals, which are useful, for instance, in screening
5 compound libraries for agents that modulate the activity of BACE455.

A further aspect of this invention resides in a vector, such as an expression or reporter vector comprising a BACE455 polynucleotide as defined above. Such vectors may be selected from plasmids, recombinant viruses, phages, episomes, artificial chromosomes, and
10 the like. Many such vectors are commercially available and may be produced according to recombinant techniques well known in the art, such as the methods set forth in manuals such as Sambrook et al., *Molecular Cloning* (2d ed. Cold Spring Harbor Press 1989), which is hereby incorporated by reference herein in its entirety.

A further aspect of this invention resides in a host cell transformed or transfected with a polynucleotide or a vector as defined above. The host cell may be any cell that can be genetically modified and, preferably, cultivated. The cell can be eukaryotic or prokaryotic, such as a mammalian cell, an insect cell, a plant cell, a yeast, a fungus, a bacterial cell, etc. Typical examples include mammalian primary or established cells (3T3, CHO, Vero, Hela, etc.), as well as yeast cells (e.g., *Saccharomyces* species, *Kluyveromyces*, etc.) and bacteria (e.g., *E. Coli*). It should be understood that the invention is not limited with respect to any
20 particular cell type, and can be applied to all kinds of cells, following common general knowledge.

25 Nucleic Acid Probes

A specific type of polynucleotide of this invention is a nucleic acid probe that selectively hybridizes under stringent hybridization condition to a nucleic acid or fragment thereof encoding a distinctive fragment of the BACE455 polypeptide... As is well-known in
30 the art, "stringent hybridization conditions" depend upon the length of the probe and the ratio of guanine-cytosine pairs to thymine (uracil)-adenine pairs in the resulting hybrid.

Within the context of this invention, a "probe" refers to a nucleic acid or oligonucleotide having a polynucleotide sequence which is capable of selective hybridization
35 with a distinctive fragment of BACE455 RNA (or the nucleotide sequence exactly complementary thereto), and which is suitable for detecting the presence of a BACE455 RNA (or nucleic acid having its exact complementary nucleic acid sequence) in any sample

containing said RNA or complement. Probes are preferably perfectly complementary to a distinctive fragment of the BACE455 RNA. Probes typically comprise single-stranded nucleic acids of between 8 to 1400 nucleotides in length, for instance of between 10 and 1000, more preferably of between 15 and 800, typically of between 20 and 600. It should be understood that longer probes may be used as well. A preferred probe of this invention is a single stranded nucleic acid molecule of between 8 to 600 nucleotides in length, which can specifically hybridize to a distinctive fragment of BACE455 RNA.

A specific embodiment of this invention is a nucleic acid probe selective for an isoform of BACE which lacks exon 4, a nucleic acid probe that selective hybridizes to said isoform gene or RNA and does not substantially hybridize to at least one other BACE isoform containing a full length exon 4, and nucleic acid probes exactly complementary to these.

A further specific embodiment of this invention is a nucleic acid probe selective for BACE455 RNA, i.e., a nucleic acid probe that selectively hybridizes to said BACE455 gene or RNA and does not substantially hybridize to at least one other BACE isoform, and nucleic acids exactly complementary to these.

Selectivity, when used to denote nucleic acid hybridization, indicates that a probe is able to hybridization to the target sequence without substantially hybridizing to at least one other BACE-encoding nucleic acid.

Preferred probes of this invention comprise a sequence which is complementary to a distinctive fragment of the BACE455 RNA (or its exact complement). Specific examples of such probes comprise the nucleic acid sequence :

ATTGCCAGGATCATTGGA

SEQ ID NO: 12

The sequence of the probes can be derived from the sequences of the BACE455 RNA as provided in the present application. Nucleotide substitutions may be performed, as well as chemical modifications of the probe. Such chemical modifications may be accomplished to increase the stability of hybrids (e.g., intercalating groups or modified nucleotides, such as 2' alkoxyribonucleotides) or to label the probe, as disclosed above. Typical examples of labels include, without limitation, radioactivity, fluorescence, luminescence, enzymatic labelling, and the like. The probe may be hybridized to the target nucleic acid in solution, suspension,

or attached to a solid support, such as, without limitation, a bead, column, plate, substrate (to produce nucleic acid arrays or chips).

In one example, a BACE455-selective oligonucleotide probe of 15 bp exactly complementary to a distinctive fragment of the BACE455 RNA is labeled with a chemiluminescent compound such as an N-hydroxysuccinimide (NHS) ester of acridinium (e.g., 4-(2-succinimidylloxycarbonyl ethyl) phenyl-10-methylacridinium 9-carboxylate fluorosulfonate) generally as described in Weeks et al., Clin. Chem. 29: 1474-1478 (1983), and Nelson et al., U.S. Pat. No. 5,658,737, both of which are hereby incorporated by reference herein. Reaction of the primary amine of the linker arm:hybridization probe conjugate with the selected NHS-acridinium ester is performed as follows. The oligonucleotide hybridization probe:linker arm conjugate synthesized as described above is vacuum-dried in a Savant SPEED-VAC® drying apparatus, then dissolved in 8 µl of 0.125 M HEPES buffer (pH 8.0) in 50% (v/v) DMSO. To this solution is added 2 µl of 25 mM of the desired NHS-acridinium ester. The solution is mixed and incubated at 37°C for 20 minutes.

An additional 3 µl of 25 mM NHS-acridinium ester in DMSO is added to the solution and mixed gently, then 2 µl of 0.1 M HEPES buffer (pH 8.0) is added, mixed, and the tube is allowed to incubate for an additional 20 minutes at 37°C. The reaction is quenched with the addition of 5 µl 0.125 M lysine in 0.1 M HEPES buffer (pH 8.0) in DMSO, which is mixed gently into the solution.

The labeled oligonucleotide is recovered from solution by the addition of 30 µl 3 M sodium acetate buffer (pH 5.0), 245 µl water, and 5 µl of 40 mg/ml glycogen. Six hundred forty microliters of chilled 100% ethanol is added to the tube, and the tube is held on dry ice for 5 to 10 minutes. The precipitated labeled probe is sedimented in a refrigerated microcentrifuge at 15,000 rpm using a standard rotor head. The supernatant is aspirated off, and the pellet is redissolved in 20 µl 0.1 M sodium acetate (pH 5.0) containing 0.1% (w/v) sodium dodecyl sulfate (SDS).

Eleven fmoles of the labeled probe is hybridized to various amounts (0.00, 0.01, 0.02, 0.05, 0.20, 0.50, 2, 5, 20, 50, 200, 500, 2000, and 5000 fmoles) of the target BACE455 RNA. Each set consisted of 100 µl hybridization reactions containing 100 mM lithium succinate (pH 5.0), 8.5% (w/v) lithium lauryl sulfate, 1.5 mM EDTA, and 1.5 mM EGTA and each reaction mixture was incubated at 50.degree. C. for 50 minutes. Three hundred microliters of a solution containing 150 mM Na₂B₄O₇ (pH 8.6) and 1% (v/v) TRITON®. X-100 were

added to each reaction, and the mixtures incubated at 50°C for 11 minutes. The reaction mixtures were then placed into a LEADER® 50 luminometer (Gen-Probe, Inc.), and a chemiluminescent reaction initiated in each mixture upon the injection of 200 µl 0.1% (v/v) H₂O₂ and 1 mM HNO₃, followed by 200 µl of 1.5 N NaOH. Chemiluminescence was read at a wavelength range from 300 to 650 nm for 2 seconds following the second injection and compared to a negative and positive control standard. Significant chemiluminescence above the negative control indicates the presence of a BACE455-selective hybrid.

Nucleic Acid Primers

Other selective polynucleotides of this invention are nucleic acid primers for amplifying a region comprising a distinctive fragment of a BACE455 RNA or its exact complement. Such primers are designed to amplify BACE455-selective nucleic acid fragments.

Particular primers of this invention are able to selectively hybridise with a portion of a BACE455 RNA or its exact complement that flanks an isoform-specific nucleic acid sequence region, more preferably a region of BACE455 RNA resulting from the newly created junction between exon 3 and exon 5, or its exact complement. The term “flanks” indicates that the portion should be located at a distance of the target region that is compatible with conventional polymerase activities, e.g., not above 300 bp from the newly created junction, preferably not exceeding 200, 150, 100 or, further preferably, 50 bp upstream from said junction. Examples of such primers comprise or are complementary to a portion of the sequences flanking nucleotide region 567-704 in SEQ ID NO: 1. Specific examples of such primers comprise the following sequences: AGGCATCCTG (SEQ ID NO: 13), GGGCTGGCCT (SEQ ID NO: 14), ATGCTGAGAT (SEQ ID NO: 15), TGCCAG (SEQ ID NO: 16), GATCAT (SEQ ID NO: 17), TGGAGGTATC (SEQ ID NO: 18), GACCACTCGC (SEQ ID NO: 19), TGTACACAGG (SEQ ID NO: 20) or CAGTCTCTGG (SEQ ID NO: 21).

Other particular primers of this invention are able to selectively hybridise with an isoform-specific region comprising a distinctive fragment of BACE455 RNA or its exact complement, more specifically a region of BACE455 resulting from a newly created junction between exon 3 and exon 5. Such primers are advantageous in that amplification occurs only when the template comprises the isoform-specific alteration. By using such primers, the detection of an amplification product indicates the presence of BACE455 RNA. In contrast, the absence of amplification product indicates that the specific alteration is not present in the

sample. Examples of such primers comprise all or a portion of the following sequences : CAGGAT (SEQ ID NO: 22), CCAGGATC (SEQ ID NO: 23), GCCAGGATCA (SEQ ID NO: 24) or ATTGCCAGGATCATTGGA (SEQ ID NO: 25).

5 A further aspect of this invention also includes at least one pair of nucleic acid primers, wherein said pair of primers comprise a sense and a reverse primer, and wherein said sense and reverse primer allows selective amplification of the BACE455 RNA or an isoform-specific portion thereof, or the exactly complementary sequence. A further embodiment of this invention is a pair of nucleic acid primers, wherein said pair comprises a
10 sense and a reverse primer, and wherein said sense and reverse primers allow selective amplification of all or an isoform-specific portion of a BACE RNA isoform lacking all or part of exon4.

Typical primers of this invention are single-stranded nucleic acid molecules of about
15 5 to 60 nucleotides in length, more preferably of about 8 to about 35 nucleotides in length, further preferably of about 10 to 25 nucleotides in length. Their sequences can be derived or inferred directly from the nucleotide sequence of BACE455 as disclosed in this application. Perfect complementarity is preferred, to ensure high specificity. However, certain mismatch may be tolerated.

20

Inhibitory Nucleic acids

The invention also relates to nucleic acid molecules that can specifically alter expression or activity of a BACE455 polypeptide or polypeptide comprising a fragment
25 thereof (or of any BACE polypeptide lacking a functional exon4). Such inhibitory nucleic acids include antisense nucleic acids, iRNA, ribozymes, aptamers, and the like. These inhibitory nucleic acids comprise a sequence that is complementary to a portion of the target isoform gene or RNA, and cause a specific reduction in transcription or translation thereof. Absolute complementarity, although preferred, is not required.

30 Techniques for the production and use of such molecules are well known to those of skill in the art, and are succinctly described below. Oligonucleotides may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Applied Biosystems, Inc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Matsukura et al. (Gene. 1988 72:343-
35 7), etc.

Antisense deoxynucleotides have been widely used to study the effect of a given gene (for review, see Stein & Cheng, Science 261: 1004-12 (1993), and can be used on exon-exon

junctions and target specific mRNA isoform (Sugi et al. Dev. Biol. 157: 28-37 (1993); Mahon et al. Exp Hematol. 23:1606-11(1995); Desire et al. J. Neurochem. 75:151-163 (2000)).

Antisense oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be
5 modified at the base moiety, sugar moiety, or phosphate backbone, for example, (selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof) to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as
10 peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane or the blood-brain barrier (Letsinger (1989) Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556), hybridization-triggered cleavage agents (Krol (1988) Bio. Techniques 6:958-976) or intercalating agents (Zon (1988) Ann. N. Y. Acad. Sci. 616:161-72 (1990)).

The antisense oligonucleotide can be an alpha.-anomeric oligonucleotide which forms
15 specific double-stranded hybrids with complementary RNA in parallel strands (Gautier et al. (1987) Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Mayeda et al. J. Biochem. 108: 399-405 (1990)), or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).

Gene silencing can also be achieved using small interfering RNAs in mammalian
20 cells (Elbashir et al. Nature 411: 494-498; Brummelkamp et al. Science 296: 550-553 (2003) and has successfully been used in the alternative splicing context to study the functional relevance of specific isoforms (Celotto & Graveley, RNA 8: 718-724 (2002)).

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA can also be used to prevent translation of target gene mRNA and, therefore, expression
25 of target gene product (Sarver et al. (1990) Science 247:1222-1225; Rossi (1994) Current Biology 4:469-471). The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. Hammerhead ribozymes are modified ribozymes which cleave mRNAs at locations dictated by flanking regions that form complementary base pairs
30 with the target mRNA. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, 1988 (Nature) 334:585-591.

These inhibitory nucleic acids can be designed based on the sequences disclosed in
35 the present application.

Specific Ligands

The invention also relates to ligands that selectively bind a BACE455 isoform or a distinctive fragment thereof, as disclosed above.

5

Different types of ligands may be contemplated, such as specific antibodies, synthetic molecules, aptamers, peptides, and the like.

10 In a specific embodiment, the ligand is an antibody, or a fragment or derivative thereof. Accordingly, a particular aspect of this invention resides in an antibody that specifically binds a BACE455-specific epitope, more preferably an epitope generated by the deletion of all or part of exon4 (encoded by amino acids 190 to 235 of SEQ ID NO 9).

15 Within the context of this invention, an antibody designates a polyclonal antibody, a monoclonal antibody, as well as fragments or derivatives thereof having substantially the same antigen specificity. Fragments include Fab, Fab'2, CDR regions, etc. Derivatives include single-chain antibodies, humanized antibodies, human antibodies, poly-functional antibodies, etc.

20 Antibodies against human BACE455 protein may be produced by procedures generally known in the art. For example, polyclonal antibodies may be produced by injecting the protein alone or coupled to a suitable protein into a non-human animal. After an appropriate period, the animal is bled, sera recovered and purified by techniques known in the art (see Paul, W.E. "Fundamental Immunology" Second Ed. Raven Press, NY, p. 176,
25 1989; Harlow et al "Antibodies: A laboratory Manual", CSH Press, 1988 ; Ward et al (Nature 341 (1989) 544). Monoclonal antibodies may be prepared, for example, by the *Kohler-Millstein* (2) technique (Kohler-Millstein, Galfre, G., and Milstein, C, Methods Enz. 73 p. 1 (1981)) involving fusion of an immune B-lymphocyte to myeloma cells. For example, antigen as described above can be injected into mice as described above until a
30 polyclonal antibody response is detected in the mouse's serum. The mouse can be boosted again, its spleen removed and fusion with myeloma conducted according to a variety of methods. The individual surviving hybridoma cells are tested for the secretion of anti-BACE antibodies first by their ability to bind the immunizing antigen and then by their ability to immunoprecipitate BACE from cells.

35

An antibody "selective for a BACE455 polypeptide" designates an antibody that selectively binds a BACE455 polypeptide to a greater extent than other BACE isoforms, i.e.,

an antibody raised against a BACE455 polypeptide or an epitope-containing fragment thereof. Although non-specific binding towards other antigens may occur, binding to the target BACE455 polypeptide occurs with a higher affinity and can be reliably discriminated from non-specific binding. Preferred antibodies are selective for a BACE455 specific domain
5 comprising the newly created junction region between exon 3 and exon 5. Antibodies selective for said domain allow the detection of the presence of BACE455 polypeptides in a sample. The ligand may be used in soluble form, or coated on a surface or support.

Specific examples of synthetic inhibitors include Gleevec and Brefeldin A. A specific
10 example of a peptide inhibitor is BACE inhibitor III (SEQ ID NO: 3).

Detection and Diagnostics

The present invention allows the performance of detection or diagnostic assays that
15 can be used, among other things, to detect the presence, absence, or amount of BACE455 or a corresponding nucleic acid in a sample or subject. The term "diagnostics" shall be construed as including methods of detecting the BACE455 isoform, corresponding nucleic acids, and fragments of these in mammalian (preferably human) samples, diagnostics (either qualitative and quantitative), pharmacogenomics, prognostic, and so forth.

20

In a particular aspect, the invention relates to a method of detecting a BACE455 nucleic acid or polypeptide, or fragments of these in a sample, preferably, a human tissue sample, comprising contacting said sample with a specific ligand thereof and determining the formation of a complex.

25

A particular object of this invention resides in a method of detecting the presence of or predisposition to a neurodegenerative disease or an associated disorder in a subject, the method comprising detecting the presence of a distinctive BACE455 nucleic acid or polypeptide in a sample from the subject, particularly a BACE isoform lacking all of exon4,
30 even more preferably a BACE isoform having the polynucleotide or amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2, respectively.

Another embodiment of this invention is directed to a method of assessing the response of a subject to a treatment of a neurodegenerative disease or an associated disorder, the method comprising detecting the presence of a distinctive BACE455 nucleic acid or
35 polypeptide in a sample from the subject at different times before and during the course of treatment.

This invention also relates to a method of determining the efficacy of a treatment of a neurodegenerative disease or an associated disorder, the method comprising (i) providing a tissue sample from the subject during or after said treatment, (ii) determining the presence and/or abundance of a BACE455 nucleic acid or polypeptide, or distinctive fragment thereof, in said sample and (iii) comparing said presence and/or abundance to the amount of such nucleic acid, polypeptide, or fragment in a reference sample from said subject taken prior to or at an earlier stage of the treatment.

The presence (or increase) in a distinctive BACE455 polypeptide or nucleic acid in a sample is indicative of the presence, predisposition or stage of progression of a neurodegenerative disease or related disorders. Therefore, the invention allows the design of appropriate therapeutic intervention, which is more effective and customized. Also, this determination at the pre-symptomatic level allows a preventive regimen to be applied.

Determination of the presence, absence, or relative abundance of a distinctive BACE455 polypeptide or nucleic acid in a sample can be performed by a variety of techniques. More preferably, the determination comprises contacting the sample with BACE 455-selective reagents such as probes, primers or ligands, as defined above, and thereby detecting the presence, or measuring the amount, of BACE455 polypeptide or nucleic acids originally in the sample. Contacting may be performed in any suitable device, such as a plate, microtiter dish, test tube, well, glass, column, and so forth. In specific embodiments, the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array. The substrate may be a solid or semi-solid substrate such as any suitable support comprising glass, plastic, nylon, paper, metal, polymers and the like. The substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc. The contacting may be made under any condition suitable for a detectable complex, such as a nucleic acid hybrid or an antibody-antigen complex, to be formed between the reagent and the nucleic acids or polypeptides of the sample.

In a specific embodiment, the method comprises contacting a sample from the subject with (a support coated with) a BACE 455 selective antibody, as described above, and determining the presence of an immune complex. Various well-known methods for detecting an immune complex can be used, such as ELISA, radio-immunoassays (RIA), and so forth.

In another specific embodiment, the method comprises contacting a sample from the subject with (a support coated with) a BACE 455-selective nucleic acid probe, as described

above, under appropriate conditions allowing hybridization to occur, and determining the presence of a hybrid.

In another specific embodiment, the method comprises contacting a sample from the
5 subject with a nucleic acid primer as defined above, under conditions allowing nucleic acid
amplification to occur, and determining the presence of an amplification product
("amplicon"). Amplification may be performed according to various techniques known per
se in the art, such as, without limitation, by polymerase chain reaction (PCR), ligase chain
reaction (LCR), transcription-mediated amplification (TMA), strand displacement
10 amplification (SDA) and nucleic acid sequence based amplification (NASBA).

Suitable methods to detect nucleic acids in a sample include, without limitation, the
following methods: allele-specific oligonucleotide (ASO), allele-specific amplification,
Southern blot (for DNAs), Northern blot (for RNAs), single-stranded conformation analysis
15 (SSCA), fluorescent in situ hybridization (FISH), gel migration, clamped denaturing gel
electrophoresis, heteroduplex analysis, etc.

The diagnostic methods of the present invention can be performed in vitro, ex vivo or
in vivo, preferably in vitro or ex vivo. The sample may be any biological sample derived
20 from a subject, which contains nucleic acids or polypeptides, as appropriate. Examples of
such samples include fluids, tissues, cell samples, organs, biopsies, etc. Most preferred
samples are blood, plasma, saliva, urine, seminal fluid, and the like. Prenatal diagnosis may
also be performed by testing fetal cells or placental cells, for instance, the sample may be
collected according to conventional techniques and used directly for diagnosis or stored. The
25 sample may be treated prior to performing the method, in order to render or improve
availability of nucleic acids or polypeptides for testing. Treatments may include, for instance
one or more of the following: cell lysis (e.g., mechanical, physical, chemical, etc.),
centrifugation, extraction, column chromatography, and the like.

30 Therapeutics

In addition to cleaving APP-based substrates, recombinant human BACE also cleaves
a substrate with the sequence LVNM/AEGD (Lin et al. Proc Natl Acad Sci U S A.
97(4):1456-1460 (2000)), a sequence which is the in vivo processing site sequence of human
35 presenilins. Presenilin 1 and presenilin 2 are unstable proteins which are processed and
subsequently stabilized by an unknown protease (Capell et al., J. Biol. Chem. 273, 3205
(1998); Thinakaran et al., Neurobiol. Dis. 4, 438 (1998)). It is known that presenilins control

the formation of A- β peptide by cleavage of APP at the gamma-secretase site, but also the activity of BACE. Presenilins therefore enhance the progression of Alzheimer's disease. Thus, the processing of presenilins by BACE would enhance the production of A- β peptide and therefore, further stimulate the progress of Alzheimer's disease. Therefore, a BACE
5 inhibitor would decrease the likelihood of developing or slow the progression of Alzheimer's disease by inhibiting APP cleavage at the beta-secretase site and/(or) by preventing the processing of presenilins, thus indirectly inhibiting APP cleavage at the gamma-secretase site.

10 A further object of this invention is a pharmaceutical composition comprising a BACE455 inhibitor, preferably a BACE455-selective inhibitor, and a pharmaceutically acceptable carrier or vehicle. In a specific embodiment, the invention relates to a pharmaceutical composition comprising (i) a specific ligand of BACE455 or a BACE455
15 inhibitory nucleic acid molecule as described above and (ii) a pharmaceutically acceptable carrier or vehicle.

The invention also relates to a method of treating or preventing neurodegenerative diseases or an associated disorder in a subject, the method comprising administering to said subject an effective amount of a BACE455-selective inhibitor.

20

Another embodiment of this invention resides in a method of treating or preventing production or accumulation of A β peptide in a subject, the method comprising administering to said subject an effective amount of a BACE455-selective inhibitor.

25 The invention also relates, generally, to the use of a BACE455-selective inhibitor in the manufacture of a pharmaceutical composition for treating or preventing neurodegenerative diseases or an associated disorder in a subject.

As throughout this specification, most preferably the subject is a human subject.

30

The BACE455-selective inhibitor may be any agent, condition or treatment that reduces the expression or activity of a BACE455 polypeptide or a distinctive fragment thereof; or the expression, transcription or translation of a BACE455 nucleic acid or a distinctive fragment thereof in a subject. Most preferably, the BACE455-selective inhibitor is
35 specific, i.e., preferentially alters the expression or activity of a BACE455 isoform and essentially does not directly alter expression of other BACE splicing isoforms. The inhibitors

may, however, also affect wild-type BACE expression or activity to a greater or lesser extent.

BACE 455-selective inhibitors that exhibit 2-fold, or 5-fold, or 10-fold, or 30-fold, or 100-fold, and/or >1000 fold selectivity for inhibiting BACE455 activity vs. that of at least one other BACE isoform have an improved utility, compared to compounds that lack such selectivity or that significantly reduce the activity of wild-type BACE. Inhibitors that inhibit BACE455 activity and have a 2-fold or greater selectivity at inhibiting BACE455 as compared to wild type-BACE have a number of non-obvious benefits including (but not limited to) greater efficacy at inhibiting pathological disease progression, decreased side effects due to less inhibition of non-pathological A β production, and improved safety due to increased selectivity of compounds. Inhibitors can be used for the purpose of prophylactic or curative treatment of conditions including, for example, Alzheimer's disease and other conditions associated with elevated levels of A β 40 or 42 peptide, and the accumulation of the peptide in amyloid plaques. BACE455 inhibitors may be selected from peptides, proteins, nucleic acids, small drugs and the like. Typical examples include inhibitory nucleic acids and antibodies as disclosed above, as well as small drugs. Such drugs can be characterized or validated using screening approaches as disclosed below. They may be obtained from existing libraries of molecules or they can be designed using commercially available software programs and techniques familiar to those skilled in the art in organic chemistry and enzymology. Methods for making inhibitors may include (but may not limited to), combinatorial chemistry, screening of molecules libraries, rational drug design – these screening methods may employ BACE455 polypeptide or nucleic acids, or fragments of these, as elements of an assay for the selection of appropriate therapeutic candidates. Methods of inhibiting BACE455 may include, but not be limited to, the use of small molecule inhibitors, peptides, antisense oligonucleotides, iRNA, ribozymes, and blocking antibodies, i.e. agents that decrease BACE455 protein levels, activity or prevent cleavage of naturally occurring substrate in the brain.

In a particular embodiment, the BACE455 inhibitor is an antibody that binds BACE455. Antibodies can be produced by a variety of techniques that are known per se in the art. In particular, they may be produced by a method comprising immunizing a non-human animal with a BACE455 polypeptide or a distinctive fragment thereof, and collecting antibodies or antibody-producing cells from said animal. Antibodies may be monoclonals, polyclonals, as well as fragments or derivatives thereof having substantially the same antigen specificity (i.e., the ability to bind BACE455). Antibody fragments include Fab, Fab'2, CDR, etc. Antibody derivatives include single chain antibodies (ScFv), humanized antibodies,

human antibodies, recombinant antibodies, bi-specific antibodies, etc. Techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies.

- 5 Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038-1041 (1988)). In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al.,
10 Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human
15 immunoglobulin constant region, e.g., humanized antibodies.

- Human antibodies are desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods (Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958
20 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT publications WO 90/02809; WO 91/10737) using antibody libraries derived from human immunoglobulin sequences. Methods of producing such antibodies are well known in the literature, as illustrated in the following, non limiting references : Harlow et al (Antibodies: A laboratory Manual, CSH Press, 1988 ; Ward et al (Nature 341 (1989) 544)).
25 Most preferred antibodies selectively bind BACE455, e.g., bind an epitope that is distinctive of BACE455 as compared to other BACE isoforms.

- In an other particular embodiment, the BACE455 inhibitor is an inhibitory nucleic acid that binds BACE455 gene or RNA, preferably BACE455 RNA, and inhibits or reduces
30 the transcription or translation thereof. Such inhibitory nucleic acids can be produced as disclosed above. They preferably comprise a sequence that hybridizes to a distinctive fragment of a BACE455 RNA molecule, as disclosed above.

- In an other embodiment, the BACE455 inhibitor is a selective inhibitor such as
35 BACE inhibitor III (SEQ ID NO: 3).

BACE455 Inhibitors may be formulated in any suitable diluent, excipient, carrier or vehicle, that is compatible for pharmaceutical use. In this regard, the invention also contemplates a method of making a composition comprising a BACE455 inhibitor, the method comprising:

- 5 i) selecting a compound that inhibits BACE455,
- ii) producing said compound, and
- iii) mixing said compound with a pharmaceutically acceptable salt thereof.

Compound that inhibits BACE of the present invention can be administered orally
10 using any pharmaceutically acceptable dosage form known in the art for such administration. The vehicle may be any solution, suspension, powder, gel, etc., including isotonic solution, buffered and saline solutions, such as syrups or aqueous suspensions, etc. The compounds may be administered by any suitable route, including systemic delivery, intra-venous, intra-arterial, intra-cerebral or intrathecal injections. Repeated injections may be performed, if
15 desired. The dosage can vary within wide limits and will have to be adjusted to the individual requirements in each particular case, depending upon several factors known to those of ordinary skill in the art. Agents determining the dosage of dosage the active compounds can be the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the
20 symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.1 to about 30 mg/kg. The daily oral dosage can vary from about 0.01 mg to 1000 mg, 0.1 mg to 100 mg, or 10 mg to 500 mg per day of a compound. The daily dose may be administered as single dose
25 or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which can include sustained release or timed release
30 formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed to prevent or treat neurological disorders related to .beta.-amyloid
35 production or accumulation, such as Alzheimer's disease and Down's Syndrome.

The compounds can be administered alone, but is generally administered with a pharmaceutical carrier, with respect to standard pharmaceutical practice (such as described in Remington's Pharmaceutical Sciences, Mack Publishing).

5 Compound that inhibits BACE455 can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a host, such as a human or a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents, either administered alone, or administered with a
10 pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

 The compound that inhibits BACE455 for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes,
15 using those forms of transdermal skin patches well known to those of ordinary skill in that art.

 Oral administration in the form of a tablet or capsule containing the active compound can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as
20 lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also
25 be incorporated into the mixture. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisole or alpha-tocopherol. Suitable binders include starch, gelatin, natural sugars such as glucose or .beta.-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or
30 sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

35

 Compound that inhibits BACE455 can also be administered in the form of liposomal particulate delivery systems, such as small unilamellar vesicles, large unilamellar vesicles,

and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines. Alternatively, compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers, such as polymers made of polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide – phenol, polyhydroxyethylaspartamide - phenol, or polyethyleneoxide - polylysine substituted with palmitoyl residues. Polymers may also belong to the class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polycyanoacrylates, etc... or block copolymers of hydrogels.

Compounds for the present invention may be formulated into gelatin capsules with the addition of lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like as powdered carriers. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. The therapeutic compositions and methods of this invention can be used to inhibit the progression of pathological diseases such as (but not limited to), Alzheimer's, dementia, glaucoma, Parkinson's, ALS, and stroke. Within the context of this invention, the term "treatment" designates preventive or curative treatments of neurological disorders, including at early or late stages of progression. Treatment includes delaying disease progression, reducing A β peptide production or accumulation, ameliorating the patients' condition, etc. Treatment can be used alone or in combination with other active agents.

Drug Screening

In another embodiment, the present invention also provides novel targets and methods for the screening of drug candidates or leads. The methods include binding assays and/or functional (activity) assays, and may be performed in vitro, in cell systems, in animals, etc.

5

A particular object of this invention resides in a method of selecting, characterizing, screening or optimizing a biologically active compound, said method comprising contacting in vitro a test compound with a distinctive BACE455 nucleic acid, polypeptide, or fragment of one of these, and determining the ability of said test compound to bind and/or influence the activity of said BACE455 nucleic acid or polypeptide. Binding alone provides some indication as to the ability of the compound to modulate the activity of said target, (although non-binding allosteric inhibitors may also be useful in, and are included within the scope of, the therapeutic methods of the present invention) and thus to affect a pathway leading to neurodegenerative disorders. In a presently preferred embodiment, the method comprises contacting in vitro a test compound with a distinctive BACE455 polypeptide or fragment thereof and determining the ability of said test compound to bind said polypeptide or fragment. The fragment preferably comprises an isoform-specific domain and/or a catalytic domain.

20 The determination of binding may be performed by various techniques, such as by labelling of the test compound, by competition with a labelled reference ligand, or other direct or indirect means of detecting a binding complex.

A further embodiment of the present invention resides in a method of selecting, characterizing, screening or optimizing a biologically active compound, said method comprising contacting in vitro a test compound with a BACE455 polypeptide and determining the ability of said test compound to modulate the activity of said polypeptide. In a specific embodiment, the test compound is contacted with a BACE455 polypeptide in the presence of BACE substrate (e.g., APP or an appropriate fragment thereof), and any changes in BACE455 activity, for example, proteolytic activity) is observed. In a preferred embodiment, the method comprises determining whether the test compound selectively affects BACE-mediated hydrolysis of the substrate. Typically, the test is carried out using a cell (e.g., a recombinant host cell) that expresses a BACE455 polypeptide.

35 A further embodiment of this invention resides in a method of selecting, characterizing, screening and/or optimizing a biologically active compound, said method

comprising contacting a test compound with a BACE455 RNA and determining the ability of said test compound to modulate the translation of said BACE455 RNA.

5 Selectivity of the compound may be assessed by determining the effect thereof on other BACE splice isoforms that contain a full length exon 4.

The above screening assays may be performed in any suitable device, such as plates, tubes, dishes, flasks, etc. Typically, the assay is performed in multi-well microtiter dishes. Using the present invention, several test compounds can be assayed in parallel. Furthermore,
10 the test compound may be of various origin, nature and composition. It may be any organic or inorganic substance, such as a lipid, peptide, polypeptide, nucleic acid, small molecule, in isolated or in mixture with other substances. The compounds may be all or part of a combinatorial library of compounds, for instance.

15 Further aspects and advantages of this invention will be disclosed in the following examples, which should be regarded as illustrative and not limiting the scope of this application. The entire contents of all publications, patents or patent applications cited throughout the present specification and examples is incorporated therein by reference.

20 EXAMPLES

Example 1: DATAS technology identifies alternative splicing events in human BACE

The DATAS technology for expression profiling studies (detailed in e.g., Patent Number
25 US6,251,590, hereby incorporated by reference herein) was used to compare alternatively spliced RNA present in the prefrontal cortex of well characterized AD patients and healthy controls. Control subjects were non-demented, were age-matched and the brain tissue was of similar age post-mortem to filter out age-related and mRNA stability-related changes in profiling studies.

30 The EXH-NADC5033 DATAS fragment aligns with NM_012104, which contains the coding sequence of the BACE501 protein (variant a isoform). Due to the differences in these two sequences, the existence of EXH-NADC5033 variant indicates a dysregulation of normal RNA splicing events in the brain of patients suffering from AD.

35 Through various alternative splicing events at the level of Exon 3 and 4 in the BACE sequence, different isoforms have been previously described (transcript variant-a to -d)

(Bodendorf et al., J Biol Chem. 276(15):12019-12023 (2001), Zoharet al., Brain Res Mol Brain Res. 115(1):63-68 (2003), Tanahashi and Tabira, Neurosci Lett. 307(1):9-12 (2001), hereby incorporated herein by reference).

- 5 The following primers were used to confirm the existence of alternative RNA splice events associated with this DATAS fragment:

PR_NM_012104-F01 (position on BACE501 coding sequence 3760-3780) (SEQ ID NO: 26) and PR_NM_012104-R01 (position on BACE501 coding sequence 4312-4330) (SEQ ID NO: 27) for the amplification of nucleic acid fragments encompassing the DATAS fragment
10 and PR_NM_012104-F02 (position on BACE501 coding sequence 698-716) (SEQ ID NO: 28) and PR_NM_012104-R02 (position on BACE501 coding sequence 1158-1178) (SEQ ID NO: 29) for the amplification of nucleic acid fragments encompassing the RNA region subjected to previously identified alternative splicing events (transcript variant-a to -d) (Bodendorf et al., J Biol Chem. 276(15):12019-12023 (2001), Zoharet al., Brain Res Mol
15 Brain Res. 115(1):63-68 (2003), Tanahashi and Tabira, Neurosci Lett. 307(1):9-12 (2001)).

Total RNA from human brain isolated from prefrontal cortex of well characterized AD patients was isolated using Trizol (Invitrogen). One microgram of RNA was reverse transcribed in 35 µL using Superscript RT kit (Invitrogen) at 42 degrees C for one hour,
20 followed by an incubation with 1 µl RNase One (Promega) for 15 min at 37 degrees C. PCR were conducted on 1/10th of the reverse transcripts with 1.5 mM MgCl₂, 0.2 mM dNTP, 1 µM of each primer. Conditions were: 3 min at 94 degrees C and 30 cycles of 94 degrees C for 30 seconds, 60 degrees C for 30 seconds and 72 degrees C for 45 seconds. After a final elongation of 5 min at 72 degrees C, PCR fragments corresponding to the full length cDNAs
25 were analyzed on a 1.5% agarose gel, cloned into TOPO TA vector using the TOPO TA cloning kit (Invitrogen) and ligation products were transformed into TOP10 E. Coli cells (Invitrogen). Cells were grown in 96 well plates overnight at 37 degrees C and colonies were picked and amplified overnight at 37 degrees C in 2XTY bacterial culture medium in the presence of ampicilin.

30 Prior to sequencing, a PCR using SP6 and T7 primers (1 µM each, Invitrogen) were conducted at 55 degrees C for 30 cycles on 1 µl aliquot of each culture.. Five µl of the PCR reaction were run on a 1.5% agarose gel, and the remaining of the PCR products were purified on P100 Bio-Gel (Biorad) columns. Sequence reaction was conducted using ABI Prism Big Dye Terminator Cycles Sequencing Ready Reaction kit version 3.0 (Aplera) and
35 reaction products were purified on G50 Sephadex columns (Amersham) and analyzed on a 3100 Genetic Analyser sequencer (Applied Biosystems).

Batch cloning and sequencing of all PCR products revealed the existence of two different transcripts corresponding to BACE501 transcript variant a and b plus a new isoform.

Analysis of the protein encoded in part by the DATAS fragment was deduced, assuming that the DATAS fragment was the locus of variation between BACE501 and BACE455. This protein shows high homology to the aspartic proteinase 2 BACE (or ASP2) described by Sinha et al., Nature 402, 537-540 (1999) and Vassar et al., Science 286, 735-741 (1999), both of which are incorporated by reference herein. Searches in various public ETSs databases such as Genbank, DDBJ (DNA Data Bank of Japan), and EMBL (European Molecular Biology Laboratory) using publicly available bioinformatic tool such as BLAT (Kent, Genome res. 12: 656-664 (2002)) or using the commercially available DoubleTwist Annotated Human Genome Database and the DoubleTwist Annotated Human and Mouse Gene Indices (produced by DoubleTwist, Inc.) failed to identify the new transcript isoform. The new transcript isoform was named BACE455 following the nomenclature from the literature (Bodendorf et al., J Biol Chem. 276(15):12019-12023 (2001), Zoharet al., Brain Res Mol Brain Res. 115(1):63-68 (2003), Tanahashi and Tabira, Neurosci Lett. 307(1):9-12 (2001)). Based on alignment with BACE501 and other isoforms, it was determined that BACE455 transcript lacks exon4.

Example2: Molecular cloning of human BACE455, a new alternatively spliced form of BACE

The full length BACE501 cDNA and the cDNA of BACE455 were subsequently cloned from the same starting material from Alzheimer brain using the GC-RICH-PCR-system (Roche Molecular Biochemicals). (Capell et al., J. Biol. Chem. 275: 40, 30849-30854 (2000)). Reverse transcribed RNA (see Example 1) were amplified with the following primers: PR_NM_012104-F03 (position on BACE501 coding sequence 442-459) (SEQ ID NO.6) and PR_NM_012104-R03 (position on BACE501 coding sequence 1971-1984) (SEQ ID NO.7) used at the concentration of 1µM in the presence of 1.5 mM MgCl₂, using the manufacturer's specifications. PCR products corresponding to the full length cDNAs of BACE501 and BACE455 were cloned into TOPO TA vector as described in Example 1 and sequenced using SP6 and T7 primers and primers PR_NM_012104-F01 (SEQ ID NO: 26), PR_NM_012104-F02 (SEQ ID NO: 28) and PR_NM_012104-R02 (SEQ ID NO: 29).

To enrich the cDNA population in cDNA corresponding to BACE455 isoform, 20µl of the first strand reverse transcripts reaction was subjected to second strand synthesis in Second Strand Buffer (Gibco) containing DNA polymerase I, dNTP mix 10 mM, RNase H (E. Coli, Gibco) and DNA ligase (E. Coli, Gibco) for 2 hrs at 16 degrees C. Then, double strand

cDNA (dscDNA) were Phenol/Chlorophorm/Isoamyl alcohol (24:25:1, v/v) - extracted and precipitated. dscDNA were then digested with restriction enzymes, *Stu*I or *Bcl*I (New England Biolabs). The digestion reaction was conducted for 2 hrs at 37 degrees C in 20 μ l using one fifth of the purified dscDNA reaction product. BACE 455 can not be cut by *Stu*I or *Bcl*I, which cut in the deleted DNA fragment, while BACE501 is digested and can not be amplified by PCR. BACE455 was PCR amplified (60 °C, 30 cycles) using primers PR_NM_012104-F03 (position on BACE501 coding sequence 442-459) (SEQ ID NO: 30) and PR_NM_012104-R03 (position on BACE501 coding sequence 1971-1984) (SEQ ID NO: 31) used at the concentration of 1 μ M in the presence of 1.5 mM $MgCl_2$ SP6 and T7 primers and primers PR_NM_012104-F01 (SEQ ID NO: 26), PR_NM_012104-F02 (SEQ ID NO: 28) and PR_NM_012104-R02 (SEQ ID NO: 29). PCR product corresponding to the full length cDNA was analyzed on a 1.5% agarose gel, subcloned into TOPO TA vector as described in Example 1 and sequenced.

After full length cloning and sequencing, the full length nucleotide (SEQ ID NO: 1) and predicted amino acid (SEQ ID NO: 2) sequences of BACE455 were determined. Results and alignments are shown in Figure 1.

BACE501 was also cloned from an EST found in the EST IMAGE database: BC036084, clone MGC:33762. The corresponding bacterial strain # MHS1010 containing the EST sequence was obtained from Open Biosystem (Huntsville, AL). PCR were conducted using the GC-RICH-PCR-system (Roche Molecular Biochemicals), using the manufacturer's specifications and primers PR_NM_012104-F03 (SEQ ID NO: 30) and PR_NM_012104-R03 (SEQ ID NO: 31) at 1 μ M and 1.5 mM $MgCl_2$. PCR products were analysed on a 1.5 % agarose gel and cDNA corresponding to the full length sequence were cloned into TOPO TA vector as described in Example 1 and sequenced using SP6 and T7 primers and primers PR_NM_012104-F01 (SEQ ID NO: 26), PR_NM_012104-F02 (SEQ ID NO: 28) and PR_NM_012104-R02 (SEQ ID NO: 29).

The new BACE variant named BACE455 completely lacks the BACE501 exon 4, resulting from an in-frame 138 bp deletion located between the two active aspartate residues within the solvent-exposed α -helix bridging the two extracellular lobes of the BACE501 protein (amino acid residues 190 to 235). Based on the BACE501 crystal structure published by Hong et al., Science. 290(5489):150-3 (2000), it appears that the active site of BACE455 is more open and accessible and is therefore likely to produce significantly increased levels of A β peptide.

The new shorter protein contains 455 amino acid residues and has a theoretical molecular weight of about 50 kDa. BACE455 contains the pro-region, an aspartic protease region, the trans-membrane region near the C-terminus and the N-linked glycosylation site essential for correct BACE processing (Asn153 and Asn 172) system (Fluhrer, R. et al.; J Biol Chem. 278(8):5531-5538 (2003), Haniu, M. et al. J. Biol. Chem. 275:21099-106 (2000)), suggesting that the novel BACE455 variant is correctly processed and matured in the secretory pathway. The active enzyme is BACE455 and the pro-enzyme is pro-BACE455.

Recent data by Huse et al. (J Biol Chem. 278(19):17141-9 (2003)) have demonstrated that BACE β -secretase activity is partially terminated by endoproteolytic cleavage of BACE1. This recently discovered process occurs on the α -helix between the two extracellular lobes (between Leu228 and Ala229) of BACE. Cleavage at this site by an unknown protease has been reported to result in the generation of distinct N- and C-terminal fragments each of ~ 37 kD in size. The two fragments are apparently maintained in a pseudo-active conformation by disulfide bonds, leading to a significantly attenuated, but not abolished, enzymatic activity. Importantly, BACE455 is not a substrate for this endoproteolytic processing, since this region is encoded by the deleted exon4.

Example 3: BACE455 shows comparable immunoreactivity with that of BACE501 in transfected mammalian cells

BACE has a half-life in the cell of greater than 9h (Haniu et al., J. Biol. Chem. 275: 21099-21106 (2000)) and cycles several times to the membrane during this period of time. Therefore, using antibodies specific of its N-terminal portion, BACE can be immunolocalized at the cell surface of intact cells (i.e. non permeabilized) and inside the cell (Golgi and endosomal compartments) in permeabilized cells. In contrast, BACE variants such as BACE457 which are inactive and whose transport along the secretory pathway is deficient and blocked at the level of the endoplasmic reticulum, can not be detected at the cell surface (Bodendorf et al., J Biol Chem. 276: 2019-23 (2001)). Therefore, immunohistochemistry studies can determine whether a given BACE variant such as BACE455 is present at the same intracellular sites as APP, or both intracellular and extracellular as BACE501, which is a prerequisite for its amyloidogenic activity.

Material and Methods

To create pCDNA3-based expression vectors, full length cDNA of BACE501 and BACE455 in TOPO TA vector were subcloned into pCDNA3 (Invitrogen) at the EcoR1 site to create pCDNA3-BACE501 and pCDNA3-BACE455, respectively. The cDNA (200 ng

plasmid/sequencing reaction) were sequenced for verification and orientation of the insert using SP6 and T7 primers from Invitrogen using the protocol described in Example 1.

NIH3T3 cells (ATCC # CRL 1658) were used to study BACE immunoreactivity because of the large size of their cytoplasm and their murine origin. Cells are routinely grown at 37°C and 5% CO₂ in Dulbecco's modified Eagle's medium with 4.5 g/l glucose and supplemented with 10% newborn bovine serum, 1% penicillin/streptomycin in T150 culture flasks. Cells are plated at 40,000 cells/well of a 6-well plate the day before transfection. Transient transfection experiments are performed with pcDNA3-BACE501, pcDNA3-BACE455 or pcDNA3-GFP (1 µg vector/well) and the Lipofectamine Plus reagent (Life Technologies) using the manufacturer's recommendations. Two days after transfection, cells are processed for immunolocalization or functional assays.

Transfected cells are cultured on poly-D-lysine-coated glass coverslips. For immunostaining, cells are fixed in 3% paraformaldehyde at 20 °C. Cells were either permeabilized with Triton X100 (0.1 % in PBS) or processed intact (no permeabilization). After blocking with 3% bovine serum albumin in phosphate buffered saline, permeabilized or intact cells are incubated with the rabbit anti-human BACE antibodies raised against the amino acid sequences 46-65 or 487-501 (Calbiochem) at 1:800 dilution. Cy3- or FITC- conjugated secondary antibodies (Sigma) are used at 1:800 dilution. Stained cells are embedded in FluorSave (Calbiochem).

Results

It is apparent from our results that BACE455 presents a comparable immunoreactivity to that of BACE501 both at the cell surface and in subcellular compartments (Figure 2). This indicates that exon 4 deletion in BACE455 does not affect its transport because BACE is efficiently exported to the cellular membrane. As BACE intracellular transport is intimately linked to processing and maturation, it is likely that BACE455 processing and maturation is not altered either and, consequently, that BACE455 amyloidogenic activity is not impaired when compared to that of BACE501.

Example 4: Demonstration of BACE455 Activity on Peptide Substrates

Two experiments were performed which demonstrate BACE455 activity on APP-based peptide substrates encompassing the beta site of cleavage. The amino acid sequence of the substrates corresponds to APP and mimics the mutation in APP found in a Swedish kindred with inherited AD in which KM amino acid residues are changed to NL. The Swedish mutation is known to increase cleavage of APP by the beta-secretase. In the first experiment,

increased expression of BACE455 in transfected human embryonic kidney HEK293 is shown to increase cleavage of the synthetic fluorogenic substrate.

A second set of experiments demonstrate that BACE455 exhibits similar activity efficiency in fluorogenic assay than BACE501. To do so, the well characterized human embryonic
5 kidney HEK293 cell line in a practical tool to study the function of overexpressed proteins.

Material and Methods

Mammalian Cell Transfection and clone selection:

Human embryonic kidney HEK293 cells (ATCC # CRC-1573) were transfected with
10 expression constructs using the Lipofectamine Plus reagent from Invitrogen. Cells were seeded in 10 cm culture plates to a density of 70-80% confluence. Each plate was transfected with 2 µg DNA, 8 µl Plus reagent, and 4 µl Lipofectamine in OptiMEM. After 5 h incubation, the transfection media was replaced with DMEM, 10% FBS, NaPyruvate, with antibiotics and the cells were incubated under normal conditions (37[deg.] C., 5% CO₂) for
15 72 hours. Three days post-transfection, cells were passaged into medium containing G418 at a concentration of 400 µg/ml. After fifteen days growth in selective medium, individual clones were selected plated into each well of one 96 well plate containing growth medium plus G418. Clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate. BACE455 or BACE501 expression in selected clones was assayed by Western
20 Blotting and immunohistochemical analysis using C-terminal-specific antibody as in Example 3. The final BACE455 or BACE501 cell lines selected exhibited the highest expression level of BACE455 or BACE501, respectively.

Preparation of Cell Extracts, Fluorogogenic assay Protocol

25 Cells were harvested and centrifuged at 1,500 rpm for 5 minutes to remove the medium. The cell pellets were washed once with PBS. To further compare BACE455 activity with that of BACE501, an in vitro assay was developed based on quenched fluorogenic substrate (Substrate V, Calbiochem) containing the Swedish mutation KM->NL in APP. Sequence of the peptide was: MCA-SEVNLDAEFK(DNP)-CONH₂ (SEQ ID NO: 32), containing the
30 Swedish APP mutation (in boldface), 7-amino-4-methyl coumarin (MCA) as the fluorophore and dinotrophenol (DNP) as the quencher. When cell lysates of BACE455 and BACE501 expressing cells are incubated with the fluorogenic Substrate V, upon cleavage by the protease, the fluorophore is separated from the quenching group, restoring the full fluorescence yield of the donor. (Ermolief et al., Biochemistry 39: 12450-12456 (2000);
35 Ellerby et al. J Neurosci. 17: 6165-6178 (1997); Capel et al., J Biol Chem. 277: 5637-43 (2002)).

- Mock transfected HEK293 and HEK293-BACE455 and -BACE501 cells were harvested by scraping in ice-cold 20 mM Tris / 150 mM NaCl, pH 7.5 plus Complete Protease Inhibitor Cocktail (Roche Diagnostics). Cells were lysed by repeated freeze-thawing and a postnuclear fraction was generated after centrifugation at 500g for 10 min. Pellets were resuspended in
- 5 membrane extraction buffer (20 mM MES / 1% Triton X100) containing protease inhibitor cocktail and incubated on ice for 30 minutes. The assay was carried out in black 96 well plates (ATGC) in a volume of 200 μ l of the membrane preparation diluted in reaction buffer (25 mM MES / 25 mM Sodium Acetate / 25 mM Tris, pH 4.4) containing 15 μ M peptide Substrate V. These components were equilibrated to 37[deg.] C. for various times and the
- 10 reaction initiated by addition of substrate. Excitation was performed at 320 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 420 nm. To test the effect of pH, lysed cells were resuspended in 25 mM MES / 25 mM Sodium Acetate / 25 mM Tris adjusted at pH values ranging from 4.4 to 8 and then incubations were performed as above.
- 15 Controls included purified recombinant human BACE501 protein (R&D Systems), or substrate alone and background fluorescence is subtracted to recorded BACE isoforms activities.

Results

- 20 BACE455 extracted from the membrane fraction generated a time dependent-increase in the fluorescent signal in the proteolysis assay, indicating that BACE455 possesses beta-secretase activity. Maximal proteolysis was seen after 2 hours, after which a plateau was reached, probably due to substrate depletion following complete cleavage.

25 Table 2: BACE activity over time

Time (min)	15	60	120	240
BACE455	125.18+-13.1	195.48+-17.0*	227.65+-15.0*	238.86+-8.4*
BACE501	119.97+-16.4	192.36+-11.26*	225.64+-23.23*	249.41+-23.88*
Mock	102.46+-7.58	134.96+-10.8	151.97+-11.3	158.28+-15.9

*: $p < 0.05$, Wilcoxon test. Shown results are mean fluorescence signals \pm SEM of at least 3 independent experiments performed with BACE455, BACE501 or mock-transfected cells

Exemple 5: Specificity of BACE455 Activity

BACE455 specificity on APP-based peptide substrates was assessed by performing the beta-secretase assay in the presence of a well characterized commercial BACE501 inhibitor, BACE inhibitor III. More important, using a dose response experiment, we show that
5 BACE455 displays an inhibitory profile significantly different from that of BACE501.

Material and Methods

BACE inhibitor III (H-Glu-Val-Asn-Statine-Val-Ala-Glu-Phe-NH₂) (SEQ ID NO: 33) from Calbiochem, is a substrate analog inhibitor of BACE. It was previously shown to completely
10 block the proteolytic activity in solubilized membrane fractions from BACE transfected cells (Capel et al., J. Biol. Chem. 277: 5637-43 (2002). Pepstatin A, Chymostatin, E64c, Leupeptin (Sigma) are inhibitors of cathepsin D (and other aspartyl proteases), or serine proteases and cysteinyl proteases, respectively.

Protease inhibitors were added to 100µl reaction buffer (25 mM MES / 25 mM Sodium
15 Acetate / 25 mM Tris, pH 4.4) at a final concentration of 100µM. When indicated, the assay buffer had a pH ranging from 4.4 to 8. Membrane preparations were obtained as in Example 4 and incubated with the inhibitors for 10 min at room temperature. Reaction was then started by adding 100 µl of reaction buffer containing the substrate (15µM final concentration) and monitored as described in Example 4. For the dose-response experiment
20 of Figure 3, Inhibitor III was assayed at various concentrations ranging from 100 µM to 100nM

Results

There was a small inhibitable activity irrespective of BACE455 or BACE501 overexpression
25 by non BACE-specific inhibitors. This can be attributed to other non-BACE membrane-bound proteases co-purified during this assay. However, in BACE455 or BACE501 extracts, substrate cleavage activity was overall very weakly sensitive to both the pepstatin and the other protease inhibitors, which are inhibitors of cathepsin D (and other aspartyl proteases), or serine and cysteinyl proteases, respectively. This suggests that non-BACE proteolytic
30 activities contribution to to substrate cleavage is minor.

In contrast, BACE inhibitor III at 100µM completely abolished BACE455 activity, as well as BACE501 activity, demonstrating the specificity for BACE-mediated cleavage of the fluorogenic substrate.

Table 3: Percentage of BACE455 inhibition by various inhibitors

	Inhibitor III	Pepstatin A	Chymostatin	E-64c	Leupeptin
BACE455	104,16	14,39	25,90	12,23	17,27
BACE501	117,54	13,14	20,44	13,14	8,03

Shown results are mean percentage of cleavage inhibition +- SEM in BACE455, BACE501 or mock-transfected cell extratct plus the indicated inhibitor (100 μ M each).

5

To further study BACE455 inhibitory profile and compare it to that of BACE501, a dose-response experiment was performed (see Figure 3). At a concentration of 10 μ M for Inhibitor III, BACE455 activity was 36.04+-4.13 % (+-SEM) while BACE501 activity was 57.6+-3.12 % (+-SEM) when compared to mock transfected control. At a concentration of 1 μ M for Inhibitor III, BACE455 activity was 57.52+-9.08 % (+-SEM) while BACE501 activity was 85.15 +-2.93 % (+-SEM) when compared to mock transfected control. It is thus apparent that for a given concentration of inhibitor, BACE455 is less inhibited than BACE501, which suggests that BACE455 is significantly different from BACE501 in terms of inhibitory profile and that the deletion of exon4 in BACE455 generates a significant pharmacological difference when compared to BACE501.

15

Exemple 6: acidic pH requirement for BACE455 activity

BACE is an acidic aspartyl protease mainly localized in the Golgi apparatus and in endosomal compartments and cleaves APP in these acidic compartments. BACE is virtually inactive at pH values of 6.0 and above ((Vassar R. et al. Science 286, 735-741 (1999); Lin X. et al. Proc. Natl Acad. Sci. USA 97, 1456-1460 (2000)). Here, we present another argument for stating that the novel BACE455 variant presents true beta-secretase activity : the strong pH requirement which is observed by BACE-specific cleavage.

25

Material and Methods

Membrane preparations were obtained as in Example 4 and incubated in assay buffer (25 mM MES / 25 mM Sodium Acetate / 25 mM Tris) adjusted to final pH ranging from 4.4 to 8, in the presence or absence of BACE inhibitor III (100 μ M final concentration). Reaction was started by adding 100 μ l of reaction buffer (pH ranging from 4.4 to 8) containing the substrate (15 μ M final concentration) and monitored as described in Example 4. We determined in these conditions the percentage of inhibition of BACE by Inhibitor III.

30

Results

Inhibitory activity of the BACE specific inhibitor was sharply maximal at pH 4.4. At pH 6 and 8, very high substrate cleavage activities were observed, unlike at pH 4.4, but were insensitive to the BACE commercial inhibitor. This is probably due to the recruitment of other proteases acting at pH6.0 or above, given that BACE is notoriously inactive at pH6 or above. These data indicate that this assay allows selective dosage of BACE455 and BACE501 secretase activity only at pH known in the literature to be relevant for BACE biological activity. In addition, the results demonstrate that BACE455 exhibits similar acidic pH dependency for activity than BACE501.

Table 4: Inhibitor-sensitive hydrolysis of Substrate V by BACE455 and BACE501-expressing cells is pH-dependent.

	% Inhibition of BACE activity by Inhibitor III			15
	pH4.4	pH 6.0	pH 8.0	
BACE455	104,16	15,97	22,10	
BACE501	117,54	13,23	17,63	

Shown results are mean percentage of cleavage inhibition in BACE455 or BACE501 cell extract performed with reaction buffer adjusted to various pH.

Thus, BACE455 and BACE501, when similarly expressed in HEK293 cells and purified using identical conditions, also cleaves the Swedish beta-secretase peptide in proteolysis assays using identical assay conditions.

Exemple 7: Effects of BACE455 and BACE501 on endogenously expressed APP isoforms processing

Proteolytic processing of APP is divided into an amyloidogenic and an antiamyloidogenic pathway. In the amyloidogenic pathway, cleavage of APP by BACE occurs at the N-terminus of the A β domain and yields the secreted sAPP β as well as a C-terminal fragment of APP of 99 amino acids (C99) of 11,145 daltons molecular weight. C99 is further cleaved within its transmembrane domain by γ -secretase, leading to the secretion of the A β peptide and the generation of the APP intracellular domain AICD. In the antiamyloidogenic pathway,

cleavage of APP by α -secretase within the A β peptide domain yields the neurotrophic and neuroprotective sAPP α .

Human cell lines that process A β peptide from APP provide a tool to screen in cellular assays for activators and inhibitors of beta-secretase. Although expression of APP, as well as
5 endogenous APP processing and release of Abeta peptide are low, SH-SY5Y human neuroblastoma cell lines (ATCC, CRL- 2266) are a usefull system to detect APP processing and the generation of C99 and A β peptide.

Material and Methods

10

Mammalian Cell Transfection and clone selection:

SH-SY5Y cells for transfection were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Transfections were performed using LipofectAmine Plus (Gibco-BRL) with 4 pcDNA3 DNA per 10*10<6 > cells. Three days
15 posttransfection, cells were passaged into medium containing G418 at a concentration of 400 μ g/ml. After twenty days growth in selective medium, individual clones were selected and plated into each well of one 96 well plate containing growth medium plus G418. Clones were expanded from the 96 well plate to a 24 well plate and then to a 6 well plate. Clones which had lost initial neuronal-like morphology were not amplified. BACE455 or BACE501
20 expression in selected clones was assayed by Western Blotting and immunohistochemical analysis using Cterminal-specific antibody. The final cell lines exhibited the highest expression level of BACE455 or BACE501 and have been maintained in G418 at 400ug/ml with passage every four days into fresh medium.

25 Preparation of Cell Extracts, Western Blot Protocol

Cells were harvested 3 days after plating. Cells were washed twice with PBS and lysed in 1 ml CellLytic solution (Sigma) plus protease inhibitors cocktail (Roche Diagnostics) for 15 min. Lysates was transferred to 1.5 ml Eppendorf tube and centrifuged at 1,500 rpm for 5 minutes. The supernatants was stored at -80[deg.] C. as the cell extracts. Equal amounts (20
30 μ g) of extracts from cells transfected with the BACE455 or control vector (Mock) were electrophoresed through 12 % Bis-Tris NOVEX gels (Invitrogen). Following electrotransfer of the separated polypeptides to PVDF membranes, APP and C99 proteolytic fragment were detected with C-terminal-specific rabbit anti-APP antibody (Serotec, UK) at 1/500 in PBS-Tween 20 0.1%, and the antibody-antigen complexes were visualized using alkaline
35 phosphatase conjugated goat anti-rabbit antibodies (1/5000). The sequence recognised by the primary antibody corresponds to amino acids 85-99 of the C99 fragment. In cells, the primary antibody also detects a non specific band migrating around 45 kDa.

Results

The effects of BACE455 on the production of C99 fragment from endogenously expressed APP isoforms were assessed in SH-SY5Y cells transfected with a construct expressing BACE455 or with the empty vector (Mock) after selection of transformants with the antibiotic G418 (Figure 4). C99 production was strongly increased in cells transformed with the BACE455 construct in comparison to those transformed with the empty vector DNA. This corresponds to increased proteolysis of endogenous APP at residues Asp-1, in a manner similar to what is described for BACE501. Also, as reported in the literature for BACE501, the overexpression of BACE455 has no influence on APP levels.

Exemple 8: Inhibitory effect of Brefeldin A and Gleevec on BACE455-dependent processing of endogenous APP isoforms

One way to interfere with BACE activity, but also APP processing, is the use of the fungal metabolite brefeldin A (BFA), which promotes fusion of the *cis*-, *medial*, and *trans*-Golgi (but not the TGN) with the ER (Lippincott-Schwartz et al. Cell 67: 601-616 (1991), or monensin, which disrupts traffic within the Golgi (Dinter et al. Histochem. Cell Biol. 109: 571-590 (1998)). Both drugs affect not only APP processing, but also BACE propeptide removal within the Golgi by inhibiting intracellular trafficking through the ER and the Golgi apparatus. As a result, in the presence of BFA, BACE overexpression leads to a reduced generation of C99 (Fischer et al. J. Neurochem. 80: 1079 (2002)).

Gleevec (imatinib mesylate) is a selective tyrosine kinase inhibitor which can inhibit A β release because it blocks γ -secretase-mediated cleavage of APP (Netzer et al. Proc Natl Acad Sci USA 100: 12444-12449 (2003)). Gleevec is a Bcr-Abl inhibitor which controls cytoskeleton, axonal development and dendrogenesis (Jones et al. J. Neurosci 24: 8510-8521 (2004)). Thus, Gleevec was tested as a pharmacological agent eventually controlling C99 generation by BACE, by impacting cell cytoskeleton and intracellular trafficking, thus preventing APP and BACE processing.

Materials and methods

BACE455 SH-SY5Y cells were treated as in Exemple 7. Cells were harvested 3 days after plating and processed for Western Blotting experiments as described above. For BFA and Gleevec treatments, cells were treated at 10 μ g/ml during the last 8 hours and at 10 μ M for the last 24 hours, respectively.

Results

To test if BFA interferes with C99 production in BACE455 cells in a manner similar to what has been reported with BACE501, BACE455 cells are treated with BFA or Gleevec and cell lysates are subjected to Western Blotting experiment using C-terminal-specific rabbit anti-APP antibody (Figure 5). As expected, in the presence of BFA which affects not only APP processing, but also BACE processing, BACE overexpression leads to a reduced generation of C99. This shows that BACE455 displays similar processing through ER-Gilgi apparatus than that of BACE501.

Gleevec treatment of BACE455 cells also strongly reduced generation of C99 peptide, Although the mechanism of action is not clear, it can involve an effect on the localization of BACE or of APP in a way that prevents interaction of APP with BACE455, probably through modifications of intracellular transport and processing.

Exemple 9: Effects of BACE455 and BACE501 on the production of A β peptides from endogenously expressed APP isoforms

Human cell lines that process A β peptide from APP provide a tool to screen in cellular assays for activators and inhibitors of beta-secretase. Multiple subcellular sites are responsible for the production of different A β peptides. The trans-Golgi network produces predominantly A β 1-40 (Xu et al., Proc. Natl. Acad. Sci. U. S. A. 94: 3748-3752 (1997), Hartmann et al. , Nat. Med. 3: 1016-1020 (1997)), although the endoplasmic reticulum/intermediate compartment produces A β 1-42 (Lee et al., J. Biol. Chem., Vol. 278: 4458-4466 (2003), Greenfield et al. Proc. Natl. Acad. Sci. U. S. A. 96, 742-747 (1999)). Production and release of A β peptide into the culture supernatant can be monitored by an enzyme-linked immunosorbent assay (ELISA). Although expression of APP, as well as endogenous APP processing and release of Abeta peptide are low, SH-SY5Y human neuroblastoma cell lines (ATCC, CRL- 2266) are a usefull system to detect Abeta processing. To do so, an isoform-specific ELISA designated for the in vitro quantitation of A β in cell extract, serum, culture medium can be used. An example of ELISA kit is the isoform-specific A β 1-40 ELISA from BioSource International.

Typically, SH-SY5Y cells cultured in normal conditions secrete around 40 pg/ml of Abeta 1-40, which is well in the detection limits and linear range of the assay (Takahashi et al., J. Biol. Chem. 278: 18664-70 (2003)). In contrast, the generation of Abeta 1-42 is weaker than Abeta 1-40 and thus cannot be detected without overexpressing APP.

35

A β ELISA Analysis (Double Antibody Sandwich ELISA for Abeta 1-40):
Cell culture supernatants harvested 72 hours after plating were analyzed in a standard double

antibody isoform-specific A β 1-40 ELISA (BioSource International) as follows. The capture rabbit antibody is specific to an epitope present on Abeta and has been coated to a 96 well immunoplate. The detecting antibody is specific for Abeta 1-40 and the conjugated secondary antibody is an anti-rabbit IgG conjugated to horseradish peroxidase. Synthetic human A β 1-40 standard peptides are serially diluted in the supplied sample diluant for the generation of standard curves. Concentrations of the peptides after dilution were: 1000, 500, 250, 125, 62.5, 31.3, 15.6 and 0.0 pg/ml in a volume of 100 μ l/well.

For quantitation in conditioned medium, 5 ml of DMEM with 1 μ M of the metalloendoproteinases inhibitor phosphoramidon is conditioned for 17 h by one 10 cm plate of 3.5×10^6 SH-SY5Y cells (plating density) and centrifuged at low speed for 5 min to remove cellular debris (Haugabook et al., J. Neurosci. Methods. 108:171-179 (2001)). Human Abeta 1-40 standards were added after washing the plate, as well as 100 μ l/well of sample, e.g., conditioned medium of transfected cells. The plate was incubated at 4[deg.] C. overnight. The next day, after washing the plate four times, 100 μ l/well rabbit detection antibody was added and incubated for 2 hours on an orbital plate shaker at 20 degree C. Following four washes, 100 μ l/well anti-rabbit IgG-horseradish peroxidase antibody (diluted 1:100) was applied and incubated for 2 hour at room temperature with shaking. After the last five washes 100 μ l/well of tetramethylbenzidine was added as chromogen substrate and the color development was allowed for 20 min at room temperature in the dark. 100 μ l/well stop solution was added and absorbance of each well was read at 450 nm within two hours, with a solution of 100 μ l each of chromogen and stop solution as the blank. All standards and samples were run in triplicates. The samples with absorbance values falling within the standard curve were extrapolated (by comparison to the values obtained for the A- β 40 and A- β 42 standard peptides analyzed on the same plate) from the standard curves and expressed in pg/ml culture medium.

Results

Effects of BACE455 or BACE501 on the production of Abeta peptides from endogenously expressed APP were assessed in SH-SY5Y cells transfected with a construct expressing BACE455 or BACE501 or with the empty vector (Mock) after selection of transformants with the antibiotic G418. A β 1-40 production was increased two times in cells transformed with the BACE455 or BACE501 construct in comparison to those transfected with the empty vector DNA. A β 1-40 levels in conditioned medium collected from cells transfected with the empty vector were 43.21 ± 1.46 pg/ml, a value well within the linear range of the assay. A β 1-40 release, expressed as the percentage of control (cells transfected with the empty vector DNA), from cells transfected with BACE455 or BACE501 was $199.95 \pm 18\%$, and

193.15±2.73 respectively ($p<0.001$ for both). This indicates that BACE455 acts to facilitate the processing and release of A β from endogenously expressed APP, as does BACE501.

In the presence of BFA which affects not only APP processing, but also BACE processing, and C99 fragment generation of which A β 1-40 is derived, A β 1-40 levels in conditioned medium were similar to that of mock transfected cells. Gleevec treatment of BACE455 cells also strongly reduced A β 1-40 release. Gleevec has been shown to block γ -secretase-mediated cleavage of APP (Netzer et al. Proc Natl Acad Sci USA 100: 12444-12449 (2003)), which is required to generate A β 1-40. Thus, our results show that Gleevec effect not only involves a reduction of γ -secretase-mediated cleavage of APP, but results from an effect on intracellular transport and processing i.e. on the localization of BACE or of APP in a way that prevents interaction of APP with BACE455.

Collectively, these data establishes that BACE455 act directly to cleave APP at the beta-secretase site, and that the rate of cleavage does not significantly differ between this isoform and BACE501 within cells. However, BACE455 activity depends on intracellular transport and processing and can be inhibited by Brefeldin A and Gleevec. BACE455 thus is an active APP-cleaving protease expressed in the brain of patients with Alzheimer's disease. Thus, the Applicants believe that BACE455 causes the accumulation of amyloidogenic A β peptides responsible for the development of Alzheimer's disease.

Table 5: Results of transfecting BACE455 or BACE501 plasmid DNA on release of A β

	A β release (% of control)
Control	100
BACE501	193.15±2.73*
BACE455	195.46±17.42*
BACE455 + 10 μ g/ml BFA	95.15±5.06
BACE455 + 10 μ M Gleevec	111.56±6.20

*: $p<0.05$, Wilcoxon test. Values tabulated are percentage of A β release ±SEM, with control set as 100%

Table1: List of primer sequences

Sequence identifier	Sequence description
SEQ ID NO.26	PCR primer PR_NM_012104-F01 (position on Refseq 3760-3780, exon1)
SEQ ID NO.27	PCR primer PR_NM_012104-R01 (position on Refseq 4312-4330, exon9)
SEQ ID NO.28	PCR primer PR_NM_012104-F02 (position on Refseq 698-716, exon5)
SEQ ID NO.29	PCR primer PR_NM_012104-R02 (position on Refseq 1158-1178, exon9)
SEQ ID NO.30	PCR primer PR_NM_012104-F03 (position on Refseq 442-459, exon1)
SEQ ID NO.31	PCR primer PR_NM_012104-R03 (position on Refseq 1971-1984, exon9)
SEQ ID NO.32	fluorogenic APP-based peptide MCA - SEVNLDAEFK(DNP) - CONH2
SEQ ID NO.33	BACE inhibitor III H-Glu-Val-Asn- Statine-Val-Ala-Glu-Phe-NH2

- Position on Refseq (NCBI Reference Sequences) refers to the position of the primer on the BACE501 nucleotidic sequence (NM_012104). RefSeq is a reference for gene identification and characterization, mutation analysis, expression studies, polymorphism discovery, and comparative analyses. The Reference Sequence (RefSeq) collection provides a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms.

CLAIMS

1. An isolated polypeptide comprising all or a distinctive fragment of BACE455.
- 5 2. The polypeptide of claim 1 comprising all or a distinctive fragment of the amino acid sequence SEQ ID NO: 2.
3. The polypeptide of claim 2, which comprises an amino acid sequence selected from the group consisting of SEQ ID Nos 3-11.
- 10 4. An isolated polynucleotide encoding the polypeptide of claim 1, 2 or 3.
5. The polynucleotide of claim 4, comprising the sequence of SEQ ID NO: 1.
- 15 6. A vector comprising the polynucleotide of claim 4 or 5.
7. A nucleic acid probe selected from the group consisting of a) a first nucleic acid that selectively hybridizes to a second nucleic acid encoding a BACE455 polypeptide or a distinctive fragment thereof, and b) a third nucleic acid that is exactly complementary to said first nucleic acid.
- 20 8. A nucleic acid primer that can be used to amplify at least a distinctive fragment of a nucleic acid molecule encoding a BACE455 polypeptide.
- 25 9. An inhibitory nucleic acid molecule, wherein said molecule hybridizes under physiological conditions to a nucleic acid molecule encoding a BACE455 polypeptide and selectively inhibits transcription or translation thereof.
- 30 10. A host cell comprising a polynucleotide of claim 4 or a vector of claim 6.
11. A polynucleotide selected from the group consisting of a) a nucleic acid comprising a first nucleotide sequence that hybridizes under stringent conditions to the nucleic acid sequence set forth in SEQ ID NO 1, and b) a nucleic acid comprising a second nucleotide sequence exactly complementary to said first nucleotide sequence.
- 35 12. A ligand able to selectively bind a BACE455 polypeptide or a distinctive fragment thereof.

13. The ligand of claim 12, which comprises a polypeptide selected from the group consisting of an antibody, a fragment of an antibody, or a derivative of an antibody.
- 5 14. The polypeptide of claim 13, which binds a distinctive fragment of a BACE455 polypeptide.
15. A BACE455 inhibitor, wherein said inhibitor inhibits the expression or activity of a BACE455 polypeptide or nucleic acid.
- 10 16. A pharmaceutical composition comprising a BACE455 inhibitor and a pharmaceutically acceptable carrier or vehicle.
- 15 17. A method of treating or preventing a neurodegenerative diseases or an associated disorder in a subject, the method comprising administering to said subject an effective amount of a BACE455 inhibitor.
- 20 18. A method of treating or preventing production or accumulation of A β peptide in a subject, the method comprising administering to said subject an effective amount of a BACE455 inhibitor.
- 25 19. A method of selecting, characterizing, screening or optimizing a biologically active compounds, said method comprising contacting a test compound with a BACE455 nucleic acid, polypeptide, or distinctive fragment of said nucleic acid or polypeptide and determining whether said test compound binds said BACE455 nucleic acid or polypeptide or modulates an activity of said BACE455 nucleic acid or polypeptide.
- 30 20. A method of detecting the presence of or predisposition to a neurodegenerative disease or an associated disorder in a subject, the method comprising detecting the presence of a BACE455 nucleic acid or polypeptide in a sample from the subject.
- 35 21. A method of assessing the response of a subject to a treatment of a neuro-degenerative disease or an associated disorder, the method comprising detecting the presence of a BACE455 nucleic acid or polypeptide in a sample from the subject.
22. A method of determining the efficacy of a treatment of a neurodegenerative disease or an associated disorder in a subject, the method comprising (i) determining the presence and/or

abundance of a BACE455 nucleic acid or polypeptide in a sample taken from said subject during or after said treatment, and (ii) comparing said presence and/or abundance to a reference sample from said subject prior to or at an earlier stage of the treatment.

- 5 23. A method for making an antibody that binds a BACE455 polypeptide, the method comprising immunizing a non-human animal with a BACE455 polypeptide or a distinctive fragment thereof, and collecting antibodies or antibody-producing cells from said animal.

- 10 24. A method of making a composition comprising a BACE455 inhibitor, the method comprising:

- iv) selecting a compound that inhibits BACE455,
- v) producing said compound, and
- vi) mixing said compound with a pharmaceutically acceptable salt thereof.

15

1/5

A

```

1 atggcccaag ccctgccctg gctcctgctg tggatgggag cgggagtgtc
51 gcctgcccac ggcaaccagc acggcatccg gctgcccctg cgcagcggcc
101 tggggggcgc ccccttgggg ctgcggctgc cccgggagac cgcagaagag
151 cccgaggagc ccggccggag gggcagcttt gtggagatgg tggacaacct
201 gaggggcaag tcggggcagg gctactacgt ggagatgacc gtgggcagcc
251 ccccgagac gctcaacatc ctggtggata caggcagcag taactttgca
301 gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct
351 gtccagcaca taccgggacc tccggaaggg tgtgtatgtg ccctacaccc
401 agggcaagtg ggaaggggag ctgggcaccg acctggtaag catcccccat
451 ggccccaacg tctctgtgctg tgccaacatt gctgccatca ctgaatcaga
501 caagtctctc atcaacggct ccaactggga aggcattctg gggctggcct
551 atgctgagat tgccaggatc attggaggtg tcgaccactc gctgtacaca
601 ggcagtctct ggtatacacc catccggcgg gagtgtgatt atgaggtcat
651 cattgtgctg gtggagatca atggacagga tctgaaaatg gactgcaagg
701 agtacaacta tgacaagagc attgtggaca gtggcaccac caaccttcgt
751 ttgcccaga aagtgtttga agctgcagtc aaatccatca aggcagcctc
801 ctccacggag aagtccctg atggtttctg gctaggagag cagctggtgt
851 gctggcaagc aggcaccacc ccttggaaaca ttttccagct catctcactc
901 tacctaattg gtgaggttac caaccagtcc ttcgcacatca ccatccttcc
951 gcagcaatac ctgcggccag tggagatgt ggccacgtcc caagacgact
1001 gttacaagtt tgccatctca cagtcattca cgggcactgt tatgggagct
1051 gttatcatgg agggcttcta cgtgtctctt gatcggggcc gaaaacgaat
1101 tggctttgct gtcagcgtct gccatgtgca cgatgagttc aggacggcag
1151 cggtggaagg cccttttctc accttggaca tggagactg tggctacaac
1201 attccacaga cagatgagtc aacctctatg accatagcct atgtcatggc
1251 tgccatctgc gccctcttca tgctgccact ctgcctcatg gtgtgtcagt
1301 ggcgtgcct ccgctgcctg cgcagcagc atgatgactt tgctgatgac
1351 atctccctgc tgaagtga

```

B

```

BACE501: 1 MAQALPWL LLMGAGVLP AHGTQH GIRLPLR SGLGGAPLGLRLPRETDEEPEEPGRGSF 60
MAQALPWL LLMGAGVLP AHGTQH GIRLPLR SGLGGAPLGLRLPRETDEEPEEPGRGSF
BACE455: 1 MAQALPWL LLMGAGVLP AHGTQH GIRLPLR SGLGGAPLGLRLPRETDEEPEEPGRGSF 60

BACE501: 61 VEMVDNLRGKSGQGYVEMTVGSPPTLNILVDTGSSNFAVGAAPHFLHRYRQLSST 120
VEMVDNLRGKSGQGYVEMTVGSPPTLNILVDTGSSNFAVGAAPHFLHRYRQLSST
BACE455: 61 VEMVDNLRGKSGQGYVEMTVGSPPTLNILVDTGSSNFAVGAAPHFLHRYRQLSST 120

BACE501: 121 YRDLRKGVVYPYTQGWEGELGTDLVSIPHGPNTVRANIAAITESDKFFINGSNWEGIL 180
YRDLRKGVVYPYTQGWEGELGTDLVSIPHGPNTVRANIAAITESDKFFINGSNWEGIL
BACE455: 121 YRDLRKGVVYPYTQGWEGELGTDLVSIPHGPNTVRANIAAITESDKFFINGSNWEGIL 180

BACE501: 181 GLAYAEIARPD DSLEPF FDSL VKQTHV PNLFS LQLCGAGFPLNQSEVLASVGGSMIIGGI 240
GLAYAEIAR IIGGI
BACE455: 181 GLAYAEIAR-----IIGGI 194

BACE501: 241 DHSLYTGS LWYTPIRREWYEVII VRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LPKK 300
DHSLYTGS LWYTPIRREWYEVII VRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LPKK
BACE455: 195 DHSLYTGS LWYTPIRREWYEVII VRVEINGQDLKMDCKEYNYDKSIVDSGTTNLR LPKK 254

BACE501: 301 VFEAAVKS IKAASSTEKF PDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRI 360
VFEAAVKS IKAASSTEKF PDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRI
BACE455: 255 VFEAAVKS IKAASSTEKF PDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRI 314

BACE501: 361 ILPQQYLR PVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSAC 420
ILPQQYLR PVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSAC
BACE455: 315 ILPQQYLR PVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSAC 374


BACE501: 421 HVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQW 480
HVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQW
BACE455: 375 HVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQW 434

BACE501: 481 RCLRCLRQQHDDFADDISLLK 501
RCLRCLRQQHDDFADDISLLK
BACE455: 435 RCLRCLRQQHDDFADDISLLK 455

```

Figure 1

2/5



3/5




Figure 3

4/5




Figure 4

5/5




Figure 5

SEQUENCE LISTING

<110> EXONHIT THERAPEUTICS SA

<120> Compositions a,d methods to inhibit the production of Abeta peptide

<130> B0229WO

<150> US 60/517,401

<151> 2003-11-06

<160> 32

<170> PatentIn version 3.1

<210> 1

<211> 1368

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1368)

<223>

<400> 1

atg gcc caa gcc ctg ccc tgg ctc ctg ctg tgg atg ggc gcg gga gtg	48
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val	
1 5 10 15	

ctg cct gcc cac ggc acc cag cac ggc atc cgg ctg ccc ctg cgc agc	96
Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser	
20 25 30	

ggc ctg ggg ggc gcc ccc ctg ggg ctg cgg ctg ccc cgg gag acc gac	144
Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp	
35 40 45	

gaa gag ccc gag gag ccc ggc cgg agg ggc agc ttt gtg gag atg gtg	192
Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val	
50 55 60	

gac Asp 65	aac Asn	ctg Leu	agg Arg	ggc Gly	aag Lys 70	tcg Ser	ggg Gly	cag Gln	ggc Gly	tac Tyr 75	tac Tyr	gtg Val	gag Glu	atg Met	acc Thr 80	240
gtg Val	ggc Gly	agc Ser	ccc Pro	ccg Pro 85	cag Gln	acg Thr	ctc Leu	aac Asn	atc Ile 90	ctg Leu	gtg Val	gat Asp	aca Thr	ggc Gly 95	agc Ser	288
agt Ser	aac Asn	ttt Phe	gca Ala 100	gtg Val	ggt Gly	gct Ala	gcc Ala	ccc Pro 105	cac His	ccc Pro	ttc Phe	ctg Leu	cat His 110	cgc Arg	tac Tyr	336
tac Tyr	cag Gln	agg Arg 115	cag Gln	ctg Leu	tcc Ser	agc Ser	aca Thr 120	tac Tyr	cgg Arg	gac Asp	ctc Leu	cgg Arg 125	aag Lys	ggt Gly	gtg Val	384
tat Tyr	gtg Val 130	ccc Pro	tac Tyr	acc Thr	cag Gln	ggc Gly 135	aag Lys	tgg Trp	gaa Glu	ggg Gly	gag Glu 140	ctg Leu	ggc Gly	acc Thr	gac Asp	432
ctg Leu 145	gta Val	agc Ser	atc Ile	ccc Pro	cat His 150	ggc Gly	ccc Pro	aac Asn	gtc Val	act Thr 155	gtg Val	cgt Arg	gcc Ala	aac Asn	att Ile 160	480
gct Ala	gcc Ala	atc Ile	act Thr	gaa Glu 165	tca Ser	gac Asp	aag Lys	ttc Phe	ttc Phe 170	atc Ile	aac Asn	ggc Gly	tcc Ser	aac Asn 175	tgg Trp	528
gaa Glu	ggc Gly	atc Ile	ctg Leu 180	ggg Gly	ctg Leu	gcc Ala	tat Tyr	gct Ala 185	gag Glu	att Ile	gcc Ala	agg Arg	atc Ile 190	att Ile	gga Gly	576
ggt Gly	atc Ile	gac Asp 195	cac His	tcg Ser	ctg Leu	tac Tyr	aca Thr 200	ggc Gly	agt Ser	ctc Leu	tgg Trp	tat Tyr 205	aca Thr	ccc Pro	atc Ile	624
cgg Arg	cgg Arg 210	gag Glu	tgg Trp	tat Tyr	tat Tyr	gag Glu 215	gtc Val	atc Ile	att Ile	gtg Val	cgg Arg 220	gtg Val	gag Glu	atc Ile	aat Asn	672
gga Gly 225	cag Gln	gat Asp	ctg Leu	aaa Lys	atg Met 230	gac Asp	tgc Cys	aag Lys	gag Glu	tac Tyr 235	aac Asn	tat Tyr	gac Asp	aag Lys	agc Ser 240	720
att Ile	gtg Val	gac Asp	agt Ser	ggc Gly 245	acc Thr	acc Thr	aac Asn	ctt Leu	cgt Arg 250	ttg Leu	ccc Pro	aag Lys	aaa Lys	gtg Val 255	ttt Phe	768
gaa Glu	gct Ala	gca Ala	gtc Val 260	aaa Lys	tcc Ser	atc Ile	aag Lys	gca Ala 265	gcc Ala	tcc Ser	tcc Ser	acg Thr	gag Glu 270	aag Lys	ttc Phe	816
cct Pro	gat Asp	ggt Gly 275	ttc Phe	tgg Trp	cta Leu	gga Gly	gag Glu 280	cag Gln	ctg Leu	gtg Val	tgc Cys	tgg Trp 285	caa Gln	gca Ala	ggc Gly	864
acc Thr 290	acc Thr	cct Pro	tgg Trp	aac Asn	att Ile	ttc Phe 295	cca Pro	gtc Val	atc Ile	tca Ser	ctc Leu 300	tac Tyr	cta Leu	atg Met	ggt Gly	912
gag Glu 305	gtt Val	acc Thr	aac Asn	cag Gln	tcc Ser 310	ttc Phe	cgc Arg	atc Ile	acc Thr	atc Ile 315	ctt Leu	ccg Pro	cag Gln	caa Gln	tac Tyr 320	960
ctg Leu	cgg Arg	cca Pro	gtg Val	gaa Glu 325	gat Asp	gtg Val	gcc Ala	acg Thr	tcc Ser 330	caa Gln	gac Asp	gac Asp	tgt Cys	tac Tyr 335	aag Lys	1008

ttt gcc atc tca cag tca tcc acg ggc act gtt atg gga gct gtt atc	1056
Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile	
340 345 350	
atg gag ggc ttc tac gtt gtc ttt gat cgg gcc cga aaa cga att ggc	1104
Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly	
355 360 365	
ttt gct gtc agc gct tgc cat gtg cac gat gag ttc agg acg gca gcg	1152
Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala	
370 375 380	
gtg gaa ggc cct ttt gtc acc ttg gac atg gaa gac tgt ggc tac aac	1200
Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn	
385 390 395 400	
att cca cag aca gat gag tca acc ctc atg acc ata gcc tat gtc atg	1248
Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met	
405 410 415	
gct gcc atc tgc gcc ctc ttc atg ctg cca ctc tgc ctc atg gtg tgt	1296
Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys	
420 425 430	
cag tgg cgc tgc ctc cgc tgc ctg cgc cag cag cat gat gac ttt gct	1344
Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala	
435 440 445	
gat gac atc tcc ctg ctg aag tga	1368
Asp Asp Ile Ser Leu Leu Lys	
450 455	

<210> 2

<211> 455

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
 1 5 10 15

Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
 20 25 30

Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
 35 40 45

Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser

BNSDOCID: <WO 2005045021A1 | >

Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly
 355 360 365

Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala
 370 375 380

Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn
 385 390 395 400

Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met
 405 410 415

Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys
 420 425 430

Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala
 435 440 445

Asp Asp Ile Ser Leu Leu Lys
 450 455

<210> 3

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 3

Ile Ala Arg Ile Ile Gly
 1 5

<210> 4

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 4

Glu Ile Ala Arg Ile Ile Gly
 1 5

<210> 5

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 5

Glu Ile Ala Arg Ile Ile Gly Gly
1 5

<210> 6

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 6

Ala Glu Ile Ala Arg Ile Ile Gly
1 5

<210> 7

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 7

Ala Glu Ile Ala Arg Ile Ile Gly Gly
1 5

<210> 8

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 8

Ala Glu Ile Ala Arg Ile Ile Gly Gly Ile
1 5 10

<210> 9

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 9

Tyr Ala Glu Ile Ala Arg Ile Ile Gly
1 5

<210> 10

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 10

Tyr Ala Glu Ile Ala Arg Ile Ile Gly Gly
1 5 10

<210> 11

<211> 11

<212> PRT

<213> artificial sequence

<220>

<223> distinctive fragment

<400> 11

Tyr Ala Glu Ile Ala Arg Ile Ile Gly Gly Ile
1 5 10

<210> 12

<211> 18

<212> DNA

<213> artificial sequence

<220>

<223> Probe

<400> 12
attgccagga tcattgga

18

<210> 13

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 13
aggcatcctg

10

<210> 14

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 14
gggctggcct

10

<210> 15

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 15
atgctgagat

10

<210> 16

<211> 6

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 16
tgccag

6

<210> 17

<211> 6

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 17
gatcat

6

<210> 18

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 18
tggaggtatc

10

<210> 19

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 19
gaccactcgc

10

<210> 20

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 20
tgtacacagg

10

<210> 21

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 21
cagtctctgg

10

<210> 22

<211> 6

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 22 caggat	6
<210> 23	
<211> 8	
<212> DNA	
<213> artificial sequence	
<220>	
<223> primer	
<400> 23 ccaggatc	8
<210> 24	
<211> 10	
<212> DNA	
<213> artificial sequence	
<220>	
<223> primer	
<400> 24 gccaggatca	10
<210> 25	
<211> 18	
<212> DNA	
<213> artificial sequence	
<220>	
<223> primer	
<400> 25 attgccagga tcattgga	18
<210> 26	
<211> 21	
<212> DNA	
<213> artificial sequence	

<220>

<223> primer

<400> 26

tgactgggaa caccataa c

21

<210> 27

<211> 19

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 27

agttgtgcat gggagcgag

19

<210> 28

<211> 19

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 28

cccgcagacg ctcaacatc

19

<210> 29

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 29

cagcgagtgg tcgatacctc c

21

<210> 30

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 30
gcggatccac catggcccaa gccc

24

<210> 31

<211> 33

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 31
ggggaattca cttcagcagg gagatgtcat cag

33

<210> 32

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> fluorogenic APP-based peptide MCA

<220>

<221> MOD_RES

<222> (10)..(10)

<223> AMIDATION

<400> 32

Ser Glu Val Asn Leu Asp Ala Glu Phe Lys
1 5 10

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB2004/003897

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N9/64 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, SCISEARCH, CHEM ABS Data, LIFESCIENCES, WPI Data, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SALANOUBAT M ET AL: "Genome sequence of the plant pathogen <i>Ralstonia solanacearum</i> " NATURE (LONDON), vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 497-502, XP002317761 ISSN: 0028-0836 the whole document	3,4
X	DATABASE EMBL 10 September 2001 (2001-09-10), "Human aspartyl protease ASP-2" XP002317765 retrieved from EBI Database accession no. AAE04797 abstract; figure 1 -/-	1,2,4,6, 8,10-15, 23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

16 February 2005

Date of mailing of the international search report

09/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Voigt-Ritzer, H

INTERNATIONAL SEARCH REPORT

Application No
PCT/IB2004/003897

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>& WO 01/46398 A (INCYTE GENOMICS, INC; KASER, MATTHEW, R; COCKS, BENJAMIN, G; LORING, J) 28 June 2001 (2001-06-28) figure 1 examples 1,7,12</p>	
X	<p>-----</p> <p>FUJIWARA HIROSHI ET AL: "Neutrophil Elastase: A Candidate Antigen for Adoptive T Cell Therapy for Myeloid Leukemia?" BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 2666, XP009044091 & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002 ISSN: 0006-4971 abstract</p>	15-18,24
A	<p>-----</p> <p>ZOHAR OFER ET AL: "Quantification and distribution of beta-secretase alternative splice variants in the rat and human brain." MOLECULAR BRAIN RESEARCH, vol. 115, no. 1, 4 July 2003 (2003-07-04), pages 63-68, XP002317763 ISSN: 0169-328X the whole document</p>	1-14, 19-23
A	<p>-----</p> <p>TANAHASHI HIROSHI ET AL: "Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production" NEUROSCIENCE LETTERS, vol. 307, no. 1, 6 July 2001 (2001-07-06), pages 9-12, XP002317764 ISSN: 0304-3940 cited in the application the whole document</p>	1-14, 19-23
A	<p>-----</p> <p>EHEHALT ROBERT ET AL: "Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 293, no. 1, 26 April 2002 (2002-04-26), pages 30-37, XP002317938 ISSN: 0006-291X page 30, column 2, paragraph 2 - page 31, column 1, paragraph 1</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-14, 19-23

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB2004/003897

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TURNER R T ET AL: "SUBSITE SPECIFICITY OF MEMAP SIN 2 (BETA-SECRETASE): IMPLICATIONS FOR INHIBITOR DESIGN" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 34, 28 August 2001 (2001-08-28), pages 10001-10006, XP001095820 ISSN: 0006-2960 the whole document -----</p>	15-18, 24
A	<p>HOM R K ET AL: "Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, no. 10, 8 May 2003 (2003-05-08), pages 1799-1802, XP002262787 ISSN: 0022-2623 the whole document -----</p>	15-18, 24

Continuation of Box II.1

Although claim 19 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 17 and 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 12,15,16,24

Present claims 16 and 24 relate to a product/compound defined by reference to a desirable characteristic or property, namely to bind or to inhibit BACE455.

The claims cover all products/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims 12, 15, 16 and 24 which appear to be clear, supported and disclosed, namely those parts relating to antibodies directed against BACE455 as well as the inhibitors Brefeldin A and Gleevec.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2004/003897

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 12, 15, 16, 24
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB2004/003897

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0146398	A	28-06-2001	US 2002169304 A1 14-11-2002
		AU 2093301 A	03-07-2001
		CA 2395286 A1	28-06-2001
		EP 1252299 A2	30-10-2002
		JP 2004500811 T	15-01-2004
		WO 0146398 A2	28-06-2001

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2004/003897

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of Item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material



a sequence listing



table(s) related to the sequence listing

b. format of material



In written format



in computer readable form

c. time of filing/furnishing



contained in the international application as filed



filed together with the international application in computer readable form



furnished subsequently to this Authority for the purpose of search

2.



In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3.

Additional comments: